Document:

EX-10.10

 Exhibit 10.10 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION 

LICENSE AGREEMENT 
 BETWEEN 

DAIICHI SANKYO COMPANY, LIMITED 

AND 
 RAIN THERAPEUTICS INC. 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION
VERSION 
 TABLE OF CONTENTS 
  

							
	 1.
	  	Definitions.	  	 	1	 
	 2.
	  	License Grants.	  	 	9	 
	 3.
	  	Development and Commercialization.	  	 	10	 
	 4.
	  	Technology Transfer.	  	 	14	 
	 5.
	  	Payments.	  	 	15	 
	 6.
	  	Intellectual Property.	  	 	20	 
	 7.
	  	Confidentiality.	  	 	24	 
	 8.
	  	Representations, Warranties and Covenants.	  	 	29	 
	 9.
	  	Indemnification.	  	 	32	 
	 10.
	  	Term and Termination.	  	 	34	 
	 11.
	  	Dispute Resolution.	  	 	40	 
	 12.
	  	Miscellaneous Provisions.	  	 	41	 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION
VERSION 
 LICENSE AGREEMENT 

This License Agreement (the “Agreement”), dated the 2nd day of
September, 2020 (the “Effective Date”), is between DAIICHI SANKYO COMPANY, LIMITED, a Japanese corporation having an office and principal place of business at 5-1, Nihonbashi-honcho 3-chome Chuo-ku, Tokyo 103-8426, Japan (“Daiichi Sankyo”), and RAIN THERAPEUTICS INC., a Delaware corporation having
an office and place of business at 8000 Jarvis Avenue, Suite 204, Newark, CA 94560, USA (“Rain”). Daiichi Sankyo and Rain are each referred to herein by name, individually as a “Party” or collectively as
“Parties”. 
 RECITALS: 

1. Daiichi Sankyo owns Patents (hereinafter defined) and Know-How (hereinafter defined) in existence
as of the Effective Date relating to the Licensed Compound (hereinafter defined); and 
 2. Rain desires to research, develop and
commercialize products containing the Licensed Compound for therapeutic uses in humans; and 
 3. Daiichi Sankyo desires to grant to Rain a
license under its Patents, and Know-How, on the terms and conditions set forth below. 
 NOW,
THEREFORE, in consideration of the foregoing recitals and the mutual agreements and covenants set forth herein, Daiichi Sankyo and Rain agree as follows: 
  

	1.	 Definitions. 

As used in this Agreement, each capitalized term used herein shall have the meaning set forth below unless context clearly and unambiguously
dictates otherwise. 
 1.1. “Affiliate” means, with respect to a Party, any person, firm, trust, corporation, company,
partnership, or other entity or combination thereof that controls, is controlled by or is under common control with such Party, for so long as such control exists. For purposes of this definition only, “control” shall mean:
(a) beneficial ownership (direct or indirect) of more than fifty percent (50%) of the shares of the entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, in the election of the
corresponding managing authority); or (b) the de facto ability to control or direct the management of such person or entity. 
 1.2.
“Applicable Laws” means any federal, state, local, national, and supranational laws, statutes, rules and/or regulations, including any rules, regulations, guidance, guidelines, or 

  
 Page 1 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
requirements of Regulatory Authorities, national securities exchanges, or securities listing organizations, that may be in effect from time to time during the Term and apply to a particular
activity hereunder and including laws, regulations, and guidelines governing the import, export, development, manufacture, transport, handling, storage, distribution, or commercialization of Licensed Compound or Product in or for the Territory
(hereinafter defined), including without limitation, the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, the European Union Data Protection Directive, Anti-Corruption Laws, Transparency Laws and Privacy Laws. 

1.2.1. “Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule” means the Standards for
Privacy of Individually Identifiable Health Information found in 45 CFR Part 160 and Subparts A and E of Part 164. 
 1.2.2.
“European Union Data Protection Directive” means Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the
free movement of such data. 
 1.2.3. “Anti-Corruption Laws” means the UK Bribery Act 2010, as amended, the
United States Foreign Corrupt Practices Act of 1977, as amended, 15 U.S.C. 78dd-1 et seq. and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or
terrorism. 
 1.2.4. “Transparency Laws” means laws related to: (i) the collection and reporting of any
payments or transfers of value to certain healthcare professionals and teaching hospitals, which include, without limitation, relevant provisions of the U.S. Physician Payments Sunshine Act (42 U.S.C. §
1320a-7h) and its implementing regulations along with similar laws and regulations in other countries; and (ii) the collection and reporting requirements, and the processing of any applicable rebate,
chargeback or adjustment, under applicable rules and regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8) and any state supplemental rebate program, Medicare average sales price
reporting (42 U.S.C. § 1395w-3a), the Public Health Service Act (42 U.S.C. § 256b), the VA Federal Supply Schedule (38 U.S.C. § 8126) or under any state pharmaceutical assistance program or U.S.
Department of Veterans Affairs agreement, and any successor government programs, as well as any registration, notification and reporting requirements under any state drug pricing transparency laws, and its implementing regulations, respectively,
along with similar laws and regulations in other countries. 
 1.2.5. “Privacy Laws” means the Health
Insurance Portability and Accountability Act (“HIPAA”), the General Data Protection Regulation 2016/679 or any other similar law to be applied in connection with safety information from any sources, to permit the sharing of safety
information. 

  
 Page 2 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 1.3. “Business Day” means a day other than a Saturday, Sunday, a day on
which commercial banks located in the United States or Japan are authorized or required by law to remain closed, or each Party’s Corporate Holiday (hereinafter defined). 

1.4. “Calendar Quarter” means each three (3) month period during a Calendar Year starting on January 1st, April 1st,
July 1st, or October 1st and ending on March 31st, June 30th, September 30th or December 31st, respectively. 
 1.5. “Calendar
Year” means each twelve (12) month period starting on January 1st and ending on December 31st. 
 1.6. “Commercially
Reasonable Effort” means, with respect to a Party, those efforts and resources, as applicable, relating to a certain activity or activities, including, without limitation, the research, development and commercialization of a Product
(hereinafter defined) in accordance with such Party’s business, legal, medical and scientific judgment, such reasonable efforts and resources to be in accordance with the efforts and resources a reasonably comparable pharmaceutical company
would use for a product owned by it, or to which it has rights, which is of similar market potential, at a similar stage in its product life, taking into account the competitiveness of the marketplace, regulatory status, relative safety and efficacy
of such product, product profile, and reimbursement considerations. Commercially Reasonable Efforts will be determined on a country-by-country basis for the applicable
Licensed Compound or Product, and the level of effort that is necessary to constitute Commercially Reasonable Effort will change over time, reflecting changes in the status of such Licensed Compound or Product (as applicable) and the market or
country involved. 
 1.7. “Competing Compound” has the meaning provided in Section 3.6.1. 

1.8. “Confidential Information” has the meaning provided in Section 7.1. 

1.9. “Conditional Approval” means, with respect to a Product, Marketing Approval (hereinafter defined) that requires, as a
condition of such approval, additional (or a continuation of) clinical trials for such Product to obtain further safety or efficacy data. 

1.10. “Continuing Clinical Trials” means on-going Phase 1 clinical trials listed on
Exhibit D which are conducted by Daiichi Sankyo or its Affiliates as of the Effective Date and will continue to be conducted by Daiichi Sankyo after the Effective Date. 

1.11. “Control”, with respect to Patents or Know-How, means possession of the ability
(whether by license or ownership, or an Affiliate having possession by license or ownership) to grant a license or sublicense, of or within the scope set forth in this Agreement, without violating the terms of any written agreement with any Third
Party. 

  
 Page 3 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 1.12. “Corporate Holiday” means, with respect to a Party, a day on which the
office of such Party is closed, and such Party gave prior notice and got prior consent from the other Party. 
 1.13.
“Cover”, “Covering” or “Covered” means, with respect to a Patent, that, but for a license granted to a Party under a claim included in such Patent, the practice by such Party of an invention claimed
in such Patent would infringe such claim (or in the case of a Patent that is a patent application, would infringe a Valid Claim in such patent application if it were to issue as a patent). 

1.14. “Daiichi Sankyo Technology” means the Daiichi Sankyo Patents and Daiichi Sankyo
Know-How. 
 1.14.1. “Daiichi Sankyo
Know-How” means (a) Know-How related to the Licensed Compound or Product that is (i) Controlled by Daiichi Sankyo as of the Effective Date or
(ii) discovered or developed from the Continuing Clinical Trials and Transferred Clinical Trials during the Term, that is reasonably necessary to research, develop, and manufacture the Licensed Compound or Product and (b) Daiichi
Sankyo’s interest in Joint Know-How. 
 1.14.2. “Daiichi Sankyo
Patents” means (a) Patents Controlled by Daiichi Sankyo as of the Effective Date or during the Term with a claim Covering the Licensed Compound or Product and (b) Daiichi Sankyo’s interest in Joint Patents. Daiichi Sankyo
Patents as of the Effective Date are set forth in Exhibit B. 
 1.15. “DMF” means a Drug Master File as more fully defined
in 21 C.F.R. §314.420 in the United States or similar documents filed with a Regulatory Authority (hereinafter defined) in another jurisdiction. 

1.16. “DS-3032b” means a compound Controlled by Daiichi Sankyo and described more
fully on Exhibit A. 
 1.17. “EMA” means the European Medicines Agency or any successor entity. 

1.18. “EU” means the European Union, as its membership may be constituted from time to time, and any successor thereto, and
which, as of the Effective Date, consists of Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal,
Romania, Slovakia, Slovenia, Spain and Sweden, and that certain portion of Cyprus included in such organization. 
 1.19.
“FDA” means the United States Food and Drug Administration or any successor entity. 

  
 Page 4 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 1.20. “Field” means all human prophylactic or therapeutic uses of the
Licensed Compound that derive therapeutic effect by binding to MDM2 for the prevention and treatment of any Indication. 
 1.21.
“First Commercial Sale” means the date on which the Product is [***] by Rain, its Affiliate, or its Sublicensee (hereinafter defined) to Third Parties (hereinafter defined) for commercial sale in any country in the Territory after
Marketing Approvals have been granted, or such sale is otherwise permitted, by the Regulatory Authority in such country, excluding samples, compassionate use (including named patient programs). 

1.22. “Full Approval” means, with respect to a Product, (a) a further Marketing Approval for such Product that was
previously granted Conditional Approval following the completion of all requirements of such Conditional Approval, or (b) a Marketing Approval that is granted, in the first instance, without any additional clinical trial requirements. 

1.23. “IND” means, in the United States, an effective Notice of Claimed Investigational Exemption for a New Drug filed with
the FDA as more fully defined in 21 C.F.R. §312.3, and, with respect to every other country in the Territory, the equivalent application (i.e., a filing that must be made prior to commencing clinical testing of Product in humans) for such
country, filed with the applicable Regulatory Authority in such country. 
 1.24. “Indication” means, with respect to a
Product, a prophylactic or therapeutic use for a particular disease or condition, with respect to which use at least one clinical trial is required to support the inclusion of such disease or condition in the indication statement of a package insert
approved by a Regulatory Authority for such Product and for which an application for Marketing Approval (or a supplement, extension or amendment thereto) must be filed to obtain such Marketing Approval by such Regulatory Authority; provided that for
clarity, the use of a Product for a disease or condition for a patient population that is a subset of the patient population for which such Product has already received Marketing Approval for such disease or condition is eligible to be an additional
Indication if it meets the foregoing requirements. For clarity, a labelling change based on the results of a clinical trial that removes a requirement for certain specified prior treatment shall be deemed a new Indication. 

1.25. “Invention” means any new or useful process, machine, manufacture, or composition of matter relating to or comprising
the Licensed Compound or Product, and any improvement, enhancement, modification or derivative work to any Daiichi Sankyo Technology, that is conceived or first reduced to practice or first demonstrated to have utility during the Term in connection
with the Parties’ activities to develop, manufacture and commercialize the Licensed Compound and Product(s) anywhere in the world. 

1.26. “Joint Technology” means the Joint Patents and Joint Know-How. 

1.26.1. “Joint Know-How” means
Know-How, including any Invention, that is conceived of, discovered, developed, made and/or reduced to practice 

  
 Page 5 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
jointly by or on behalf of employees, agents, or consultants of Daiichi Sankyo or its Affiliates, on the one hand, and employees, agents, or consultants of Rain, its Affiliates, or its
Sublicensees, on the other hand. 
 1.26.2. “Joint Patents” means Patents with a claim Covering an Invention
that is conceived of, discovered, developed, made and/or reduced to practice jointly by or on behalf of employees, agents, or consultants of Daiichi Sankyo or its Affiliates on the one hand, and employees, agents, or consultants of Rain, its
Affiliates, or its Sublicensees, on the other hand. 
 1.27. “Know-How” means
confidential and proprietary information and tangible materials, whether patentable or unpatentable, including, without limitation: (a) ideas, discoveries, Inventions, improvements or trade secrets; (b) tests, assays, techniques, methods,
procedures, formulas, processes and data, including, but not limited to, clinical data (including patient report forms, preliminary and final investigators’ reports, statistical analyses, expert opinions and reports, safety and other electronic
databases, Regulatory Filings and communications, and the like), pharmacological, preclinical and toxicological data, as well as manufacturing information and descriptions; and (c) pharmaceutical, chemical and biological materials, products and
compositions of matter. Know-How does not include any Patents. 
 1.28. “Licensed
Compound” means DS-3032b as well as any [***]. 
 1.29. “Major European
Country” means each of the United Kingdom, France, Germany, Italy and Spain. 
 1.30. “Market Exclusivity” means
exclusive right to sell a Product in a country or region as the result of applicable laws and/or regulations, including data exclusivity, pediatric exclusivity. 

1.31. “Marketing Approval” means, with respect to the Product, all approvals, licenses, registrations or authorizations of
any Regulatory Authority, necessary for the manufacturing, use, storage, import, transport and sale of such Product in any country within the Territory including Conditional Approval and Full Approval but excluding pricing or reimbursement approval
where governmental approval is required for pricing, or for the Product to be reimbursed by national health insurance. 
 1.32.
“MDM2” means the protein encoded by the human gene MDM2. 
 1.33. “NDA” means a New Drug Application,
filed with the FDA to obtain Marketing Approval for the Product in the United States, or its foreign equivalent (or a supplement, extension or amendment thereto), or any successor application having substantially the same function. 

1.34. “Net Sales” means the gross amounts invoiced for the Product sold by Rain, its Affiliates, or its Sublicensees (each a
“Selling Party”) in finished product form, packaged and labeled for sale in arm’s length transactions to Third Parties, less the following deductions from such gross amounts: [***]. Net Sales, as set forth in this definition,
will be calculated by applying 

  
 Page 6 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
the Selling Party’s standard accounting practices, in accordance with generally accepted accounting principles used by the Selling Party, as consistently applied in its respective audited
financial statements. 
 1.34.1. [***]. Additionally, the following will not be included in Net Sales: [***]. 

1.34.2. In the event that a Product is sold as part of a Combination Product, where “Combination Product” means any
unified dose of pharmaceutical product which is comprised of Product and other therapeutically active compound(s) and/or ingredients (collectively, the “Other Products”), Net Sales of Product, for the purposes of determining royalty
payments and achievement of sales milestones, shall be determined by [***]. Each of “weighted average sale price” and “reasonably estimated commercial value” shall be determined, [***], as set forth below: 

“Weighted average sale price” and “reasonably estimated commercial value,” as the case may be, for the
Product and Other Products shall be calculated once at the commencement of each [***] and such amount shall be used during all applicable royalty reporting periods for the entire following [***]. When determining the weighted average sale price of
the Product or Other Products, the weighted average sale price shall be calculated [***] (or the number of months sold in a partial [***]) of the preceding [***] for the respective Product or Other Products. “Reasonably estimated commercial
value” shall be determined by [***]. If the Parties do not agree, such dispute shall be first referred to the discussion between the Parties in accordance with Section 11.1, but if not resolved as set forth in Section 11.1, shall be
resolved in accordance with Section 11.2 hereof. In the [***] in which the First Commercial Sale occurs, [***] will be used for the Product and Other Products, if applicable. [***]. 

1.35. “Patents” means any of the following: (a) any issued and unexpired patent, including without limitation, any
inventor’s certificate, substitution, extension, re-registration, confirmation, reissue, re-examination, re-validation,
renewal or any similar governmental grant for protection of inventions (including, but not limited to, patent term extensions, pediatric exclusivity or supplementary protection certificate); (b) any patent application including, without limitation,
any continuation, divisional, substitution, continuation-in-part, provisional applications and converted provisional applications; and (c) all foreign counterparts
of any of the foregoing. 
 1.36. “Phase 2 Clinical Trial” means a human clinical trial of the Licensed Compound or
Product, the principal purpose of which is a determination of safety and efficacy in the target patient population, which is prospectively designed to generate sufficient data that may permit commencement of Pivotal Clinical Trials (hereinafter
defined), or a similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to law or otherwise, including the trials referred to in 21 C.F.R. §312.21(b), as amended, irrespective of whether it is nominally
titled or referred to as a “Phase 2 clinical trial” or “Phase 2 clinical study”. 

  
 Page 7 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 1.37. “Phase 3 Clinical Trial” means a human clinical trial of the Licensed
Compound or Product on a sufficient number of subjects in an indicated patient population that is designed to establish that the Licensed Compound or Product is safe and efficacious for its intended use and to determine the benefit/risk
relationship, warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support Marketing Approval of such Licensed Compound or Product, including all tests
and studies that are required by the Regulatory Authorities from time to time, pursuant to applicable law or otherwise, including the trials referred to in 21 C.F.R. §312.21(c), as amended, irrespective of whether it is nominally titled or
referred to as a “Phase 3 clinical trial” or“ Phase 3 clinical study”. 
 1.38. “Pivotal Clinical
Trial” means a Phase 3 Clinical Trial or any other clinical trial that has been identified by Regulatory Authority as being sufficient to obtain Marketing Approval to market the Product in such Indication. 

1.39. “Product” means any pharmaceutical preparation in any dosage form which contains the Licensed Compound as an active
ingredient, whether alone or in combination with other active pharmaceutical ingredient(s). 
 1.40. “Regulatory Authority”
means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the research, development, manufacture, commercialization or other use (including the
granting of Marketing Approvals) of the Product(s) in any country in the Territory including, with respect to the United States of America, the FDA, and with respect to the European Union, the EMA. 

1.41. “Regulatory Filings” means, collectively, all INDs for the Licensed Compound, the DMF, any application for Marketing
Approval, Marketing Approvals and other filings for the Product, such as annual reports, required by any Regulatory Authority in any country in the Territory. 

1.42. “Sublicensee” means any Third Party or Affiliate of Rain that is granted a sublicense of the rights granted in
Section 2.1 by Daiichi Sankyo hereunder in accordance with the terms of Sections 2.2 and 2.3, regardless of the number of intermediate sublicenses (tiers) granted between Rain and such Rain’s Affiliate(s) or Third Party(ies). 

1.43. “Term” has the meaning provided in Section 10.1. 

1.44. “Territory” means all countries and territories of the world. 

1.45. “Third Party” means any entity other than a Party or an Affiliate of a Party. 

1.46. “Transferred Clinical Trials” means on-going Phase 1 clinical trials listed on
Exhibit C which are conducted by Daiichi Sankyo or its Affiliates as of the Effective Date and will be transferred to Rain after the Effective Date in accordance with Section 3.1.5. 

  
 Page 8 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 1.47. “Valid Claim” means a claim of any issued and unexpired Patent (as may
be extended through supplementary protection certificate or patent term extension or the like) or pending patent application, which claim has not been revoked, held invalid, unpatentable, or unenforceable by a patent office, court or other
governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not been disclaimed,
denied or admitted to be invalid, unpatentable, or unenforceable through reissue, re-examination or disclaimer or otherwise. 
  

	2.	 License Grants. 

2.1. Scope of Grant. In consideration of and subject to the terms and conditions of this Agreement, Daiichi Sankyo grants to Rain, a
royalty-bearing, exclusive (even as to Daiichi Sankyo, except as otherwise expressly set forth herein) right and license in the Field in the Territory, with the right to grant one or more sublicenses through multiple tiers in accordance with the
terms of Sections 2.2 and 2.3, under the Daiichi Sankyo Technology: (a) to research and develop the Licensed Compound and Product; (b) to make, have made, use, import and export the Licensed Compound for the purpose of making, having made,
using, offering for sale, selling, marketing, distributing, importing and exporting Product; and (c) to make, have made, use, offer for sale, sell, have sold, market, distribute, import and export Product. 

2.2. Sublicenses. Rain may grant sublicenses of the license granted under Section 2.1, other than the right to manufacture or have
manufactured, to one or more Sublicensees without Daiichi Sankyo’s prior written consent upon giving [***] prior notice to Daiichi Sankyo. [***]. Rain may grant the right to manufacture or have manufactured the Licensed Compound or the Product
to one or more Sublicensees or the Third Parties including CMO and toll manufacturers in accordance with Section 2.3. Rain will ensure that all Sublicensees are bound by the same obligations as those set forth hereunder, including, but not
limited to the obligations of confidentiality and non-use of Confidential Information. Rain will use reasonable efforts to enforce the sublicense agreement in the case of any breach thereof that would be a
breach of the terms of this Agreement if committed by Rain. On or before [***], until the expiration or termination of the Term, Rain shall provide to Daiichi Sankyo [***] sublicense report describing: (a) identity (name and address) of all
current Sublicensees, irrespective of tiers of sublicense and (b) the nature and scope of sublicense (subject activities, geographical location, etc.). 

2.3. Approval of Manufacturer. Within [***] after the Effective Date, Rain shall provide the list of the proposed manufacturers of
Licensed Compound or Product, including information: (a) name of manufacturer, (b) address of manufacturer, (c) the location of manufacture, (d) what to manufacture (API or pharmaceutical preparation and its dosage form), (e) the
name of their sub-licensor or entity that gave manufacturing rights, and whether they will be granted a right to sublicense, and (f) in case of the manufacturer of the Product, for which countries or
regions to sell. Daiichi Sankyo shall review such list and inform Rain in writing of any potential manufacturer(s) on the list that are approved (such approval not to be unreasonably withheld, delayed or conditioned). If Daiichi Sankyo does not
notify Rain of its approval of a proposed manufacturer within [***] of receiving the list from Rain, such sublicensee shall be 

  
 Page 9 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
deemed approved. If Rain wishes to engage a manufacturer that is not on the then current list of approved manufacturers, it may request approval of such manufacturer by submitting a written
request to Daiichi Sankyo. Daiichi Sankyo shall review such request and inform Rain in writing if such proposed manufacturer is approved. If Daiichi Sankyo does not notify Rain of its approval of a manufacturer within [***] of receiving the request
from Rain, such manufacturer shall be deemed approved. Any denial of approval by Daiichi Sankyo shall be made in good faith based on reasonable concerns related to the particular manufacturer. If requested by Rain, Daiichi Sankyo shall discuss its
reasons for denying approval of a manufacturer. For clarity, approval of a manufacturer by Daiichi Sankyo does not change or limit Rain’s obligations under this Agreement. Daiichi Sankyo shall have the right to review the terms of the proposed
sublicense agreement in advance and provide comments, such comments to be considered in good faith by Rain. 
 2.4. No Other Rights.
It is expressly understood that Rain is not granted any rights to the Daiichi Sankyo Technology, except as expressly provided in Sections 2.1 and 2.2. For clarity, Rain shall not have any right to the Licensed Product out of the Field. 

 

	3.	 Development and Commercialization. 

3.1. Research and Development 

3.1.1. Responsibility. Subject to Sections 3.1.4, 3.1.5 and 3.1.6, Rain will be solely responsible at its expense for
research, development and registration of the Licensed Compound and Product in the Field in the Territory after the Effective Date. 

3.1.2. Diligence. Rain, either directly or through one or more of its Affiliates or Sublicensees, will use Commercially
Reasonable Efforts to receive at least three (3) Full Approval for use in the Field and to maintain the same during the Term in each of the following countries/region: the United States of America, each Major European Country, and one country
outside the United States of America and EU. Both Parties agree and acknowledge that failure by Rain to use Commercially Reasonable Efforts as set forth in this Section 3.1.2 will be considered a material breach of this Agreement for which
Daiichi Sankyo may terminate the Agreement in accordance with Section 10.2.1. 
 3.1.3. Further Development.
Subject to Sections 3.1.5 and 3.1.6, Rain shall conduct all clinical trials and non-clinical studies to obtain Marketing Approval(s) within the Territory. On or before [***] and [***] of each [***], Rain shall
provide Daiichi Sankyo [***] development report describing: (a) the achievement of any development milestone event described in Section 5.2 of this Agreement; (b) any other significant or material events in the development of the
Licensed Compound, and/or Product(s); (c) a summary of development milestones specified in Section 5.2 expected to be achieved for the Licensed Compound and/or each Product during the subsequent

  
 Page 10 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
[***]; and (d) a good faith projection of the current development plan for each Product. In addition to such [***] reports, Rain shall inform [***] Daiichi Sankyo in writing of any material
change to its research and development plan. 
 3.1.4. IND Transfer. Daiichi Sankyo shall transfer [***] (for [***]
study) and [***] (for [***] study) to Rain as soon as appropriate after the Effective Date and hereby assigns, effective on the date agreed by the Parties, both INDs to Rain. Rain shall be responsible for the cost of transferring the INDs. 

3.1.5. Transferred Clinical Trials. Subject to Section 3.1.4, Rain and Daiichi Sankyo shall discuss when and how
Rain takes over Daiichi Sankyo’s responsibility for Transferred Clinical Trials within [***] after the Effective Date. Rain shall be responsible for the cost of Transferred Clinical Trials incurred after the Effective Date at its own expense.
With respect to the on-going Phase 1 clinical trial of DS-3032b in combination with [***] (i.e., Daiichi Sankyo’s internal reference code for clinical trial
“[***]”) which is one of the Transferred Clinical Trials, Daiichi Sankyo and Rain shall execute an agreement for the terms and conditions that includes the following but not limited to: (i) supply of [***], (ii) regular update of
study status, (iii) safety data exchange and (iv) ownership of the results and IP. Daiichi Sankyo shall provide Rain with the draft of itemized [***] invoice for customary and reasonable Third Party costs and expenses incurred for CRO
services, data management and biostatistics after the Effective Date to continue the Transferred Clinical Trials until the transfers are completed, to the extent consistent with a budget agreed by the Parties as of the effective date of above
agreement related to [***]. Rain shall review such draft and inform Daiichi Sankyo of its comments within [***] of receiving the draft of invoice. If Rain does not notify Daiichi Sankyo of its comments, such invoice shall be deemed finalized. Rain
shall reimburse Daiichi Sankyo within [***] of receiving an itemized [***] invoice from Daiichi Sankyo. With respect to [***] study, Daiichi Sankyo shall be responsible for preparing the final report. 

3.1.6. Continuing Clinical Trials. Subject to Section 3.1.4, Daiichi Sankyo shall continue to conduct the
Continuing Clinical Trials until all subjects complete the study treatment, the clinical drug supplies in Daiichi Sankyo’s possession as of the Effective Date are depleted or the expiration date of such clinical drug supplies has passed,
whichever is the earliest. If Daiichi Sankyo makes a decision to close a Continuing Clinical Trial, Daiichi Sankyo will provide notification to Rain [***] before termination of such Continuing Clinical Trial and related contracts. Daiichi Sankyo
shall be responsible for preparing the final report for the Continuing Clinical Trials after such Clinical Trials are completed. With respect to [***] study, Daiichi Sankyo shall continue to collect trial safety data for [***] study after IND
transfer to Rain in accordance with Section 3.1.4 until completion of preparing the final report for [***] study under a pharmacovigilance agreement executed by the Parties. Daiichi Sankyo shall provide Rain with the draft of itemized [***]
invoice for customary and reasonable Third Party costs and expenses incurred for CRO services, data management and biostatistics after the Effective Date to continue the Continuing Clinical Trials, the cumulative total amount of which shall not
exceed [***]. 

  
 Page 11 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 3.1.7. Regulatory Submissions. Rain shall be responsible for the
preparation, filing and maintenance of all Regulatory Filings and related submissions with respect to the Licensed Compound and Product in the Territory and shall bear the cost of such preparation, filing and maintenance of Regulatory Filings,
except that Daiichi Sankyo shall be responsible for all such activities and costs for the Transferred Clinical Trials prior to transfer of the INDs therefor to Rain and for the Continuing Clinical Trials until all subjects complete the study
treatment, the clinical drug supplies in Daiichi Sankyo’s possession as of the Effective Date are depleted or the expiration date of such clinical drug supplies has passed, whichever is the earliest. Rain shall be responsible for all regulatory
interactions and responsibilities relating to obtaining any Marketing Approval in the Territory. 
 3.2. Commercialization. 

3.2.1. Responsibility. Rain will be solely responsible at its expense for commercialization of the Product in the Field
in the Territory. 
 3.2.2. Diligence. Rain shall have the sole responsibility to commercialize Products throughout
the Territory. Rain, either directly or through its Affiliates, and/or its Sublicensees, shall use Commercially Reasonable Efforts to launch the Product(s) in the Field as soon as reasonably practicable after receipt of the Marketing Approval and,
if applicable, pricing and reimbursement approval, in a country where such Marketing Approval and pricing and reimbursement approval was obtained, and thereafter to market, promote and sell Product(s) in the Field in such country. Both Parties agree
and acknowledge that failure by Rain to use Commercially Reasonable Efforts as set forth in this Section 3.2.2 will be considered a material breach of this Agreement, for which Daiichi Sankyo may terminate the Agreement in accordance with
Section 10.2.1. 
 3.3. Manufacturing. 

3.3.1. Responsibility. Except for materials transferred under Section 3.3.2, Rain will be solely responsible at its
expense for manufacturing of all of the Licensed Compound and Product that are necessary for further development and commercialization of such Licensed Compound and Product after the Effective Date (except for the Transferred Clinical Trials until
transferred and Continuing Clinical Trials until completion). Manufacturing of the Licensed Compound and Product may be done by Rain directly, or through an Affiliate or Sublicensee, provided that Daiichi Sankyo is informed of any sublicensing of
Daiichi Sankyo Technology as provided in Section 2.2, and Rain has obtained approval for any entity that manufactures Licensed Compounds or Products as provided in Section 2.3. 

  
 Page 12 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 3.3.2. Existing Stock of Materials. Within [***] after Rain notifies
Daiichi Sankyo of the location where the existing stock of materials will be delivered, Daiichi Sankyo will make arrangements to deliver to Rain or its designee the existing stock of the Licensed Compound and other materials that are listed in
Exhibit E. Upon request, appropriate documentation will be provided for all materials transferred pursuant to this Section 3.3.2. Such stock of the Licensed Compound and other materials set forth in this Section 3.3.2 will be provided,
[***], by Daiichi Sankyo to Rain; provided, however, that all related shipping costs and insurance shall be paid by Rain. Daiichi Sankyo hereby represents and warrants to Rain that the materials labeled “GMP” in Exhibit E have been
manufactured and stored in accordance with GMP (as defined by the FDA) and will comply with GMP at the time of delivery. 
 3.4.
Compliance. Rain and all of its Affiliates and Sublicensees will conduct all research, development, regulatory, manufacturing and commercialization activities with respect to the Licensed Compound and/or Product in compliance in all material
respects with all applicable legal requirements and regulatory standards including GLP, GCP and GMP, to the extent applicable, and in compliance with all other Applicable Laws. 

3.5. Third Party Licenses. If Rain finds any Patent that is Controlled by a Third Party and which Rain believes is necessary to
research, develop, register, manufacture and commercialize the Licensed Compound and Product in the Field in the Territory, as between the Parties, Rain shall have the sole right to obtain a license from such Third Party under such Patent(s) (a
“Third Party License”). Rain will be responsible for all obligations arising from such Third Party License executed on and after the Effective Date. In the event that Rain obtains a Third Party License, Rain shall make all required
payments thereunder without incurring any cost to Daiichi Sankyo. Rain shall not deduct any payments made under any Third Party License from its required payment to Daiichi Sankyo pursuant to this Agreement. Daiichi Sankyo will be responsible for
all obligations arising from written agreements with Third Parties executed before the Effective Date that are necessary to research, develop, register, manufacture and commercialize, or that otherwise relate to or have payment obligations in
connection with, the Product in the Territory. 
 3.6. Competing Programs. 

3.6.1. Non-Compete. During the Term, except for activities under this Agreement,
Rain shall not, itself or through its Affiliates or any Third Party, conduct or participate in any research, development, commercialization or manufacturing of any compound that derives same therapeutic effect by the same mode of action of the
Licensed Compound (“Competing Compound”) in the Territory. Daiichi Sankyo shall not develop or commercialize any product containing any Licensed Compound. 

  
 Page 13 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 3.6.2. Acquired Molecules. During the Term, if Rain or its Affiliates,
as a result of a merger or other transaction, acquires or is acquired by a Third Party that is developing and/or distributing, marketing or selling, either on its own or through such Third Party’s affiliate or licensee, a product that contains
Competing Compound, the surviving entity in such transaction shall discontinue development or commercialization of, or divest such Competing Compound within [***] after such transaction is completed (and any activities during such [***] period will
not be a breach of this Agreement). Provided however, in the case Rain is acquired by a Third Party, such Third Party shall terminate this Agreement in its entirety on written notice to Daiichi Sankyo within thirty (30) days of such transaction
if it decides not to discontinue development or commercialization of, or divest Competing Compound, in which case the effects of termination set forth in Section 10.5.1 will apply. 

3.6.3. Confidential Information. During and after the Term, Rain shall not and shall cause its Affiliates, and require
its Sublicensees, not to use any Daiichi Sankyo Technology or any Confidential Information received from Daiichi Sankyo for any purpose, including to research, develop, register, manufacture, or commercialize any compound and product other than the
Licensed Compound and Product, other than as expressly allowed under this Agreement. 
  

	4.	 Technology Transfer. 

4.1. Non-Clinical Data. Within [***] after the Effective Date, Daiichi Sankyo will provide to
Rain the non-clinical data and study reports listed in Exhibit F. Such provision of data and study reports, and any other information will be done through an electronic data room or other reasonable means, as
determined by Daiichi Sankyo after consulting with Rain. Daiichi Sankyo will provide such data and study reports in the language which it was drafted and Daiichi Sankyo shall not be obligated to translate such documents. 

4.2. Clinical Data. Within [***] after the Effective Date, Daiichi Sankyo will provide to Rain the clinical data and study reports
listed in Exhibit G. Daiichi Sankyo and/or its Affiliates will timely prepare and submit 2021 development safety update reports (“DSUR”) for the Transferred Clinical Trials and Continuing Clinical Trials. Upon a written request from
Rain, Daiichi Sankyo will transfer interim trial data and audit/compliance-related documents from the Transferred Clinical Trials and Continuing Clinical Trials to Rain. Such provision of data and study reports, and any other information, will be
done through an electronic data room or other reasonable means, as determined by Daiichi Sankyo after consulting with Rain. Daiichi Sankyo will provide such data and study reports in the language in which it was drafted and Daiichi Sankyo shall not
be obligated to translate such documents. Daiichi Sankyo hereby represents and warrants that as of the Effective Date, it is not aware of any Suspected, Unexpected, Serious Adverse Reactions (“SUSARs”) that have not been properly
reported to all applicable Regulatory 

  
 Page 14 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
Authorities. If there are any ongoing communications as of the Effective Date with respect to any SUSARs reporting, Daiichi Sankyo shall complete such reporting after the Effective Date. Rain
shall be responsible for preparing and submitting 2022 DSUR and thereafter for the Transferred Clinical Trials and Continuing Clinical Trials. 
 Rain shall
be responsible for preparing the final report for the Transferred Clinical Trials other than [***] study on its own or by another vendor of its choice, and Daiichi Sankyo shall have no responsibility for preparing such final report. 

The cost to prepare the final report for the Continuing Clinical Trials has been included in the cost to be reimbursed by Rain, as provided in
Section 3.1.6. 
 4.3. Manufacturing Technology. Within [***] after the Effective Date, Daiichi Sankyo will provide to Rain or
to a contract manufacturer selected by Rain and reasonably approved by Daiichi Sankyo in accordance with Section 2.3, the documents, reports, data, analytical reports, and other information listed in Exhibit H. Such provision of documents,
reports, data, analytical reports, and any other information will be done through an electronic data room or other reasonable means, as determined by Daiichi Sankyo after consulting with Rain. Daiichi Sankyo will provide such documents, reports,
data, analytical reports, and other information in the language in which it was drafted and Daiichi Sankyo shall not be obligated to translate such documents. 

4.4. Assistance. Following the technology transfer under Sections 4.1, 4.2 and 4.3, upon the request of Rain, appropriate personnel at
Daiichi Sankyo will remain reasonably available to answer questions and to provide other assistance regarding the transferred technology, subject to reasonable conditions and approval by Daiichi Sankyo, for up to [***] after the Effective Date. If
Rain provides Daiichi Sankyo with a good faith rationale for why it needs assistance from Daiichi Sankyo’s personnel related to its manufacturing technology in Section 4.3, Daiichi Sankyo will make such personnel available to Rain for up
to [***] after the [***] anniversary of the Effective Date. Notwithstanding above, if Rain receives inquiries from Regulatory Authorities in [***] and [***] for information not available in the transferred technology, Daiichi Sankyo will provide
reasonable assistance. 
 4.5. Reimbursement for Assistance. Rain shall reimburse Daiichi Sankyo for reasonable out-of-pocket expenses that are required to provide assistance under Section 4.4 to Rain and shall pay Daiichi Sankyo a rate of [***] per day per person for the time
expended by Daiichi Sankyo personnel for travel outside of Japan requested by Rain. All extraordinary costs shall be subject to the Parties’ agreement. 
  

	5.	 Payments. 

5.1. Upfront Payment. In consideration of Daiichi Sankyo’s grant of the rights and licenses to Rain hereunder, Rain will pay
Daiichi Sankyo a non-refundable, non-creditable payment of five million Dollars ($5,000,000) within [***] of the Effective Date. 

  
 Page 15 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 5.2. Development Milestones. As further consideration for Daiichi Sankyo’s grant
of the rights and licenses to Rain hereunder, Rain shall pay Daiichi Sankyo the following nonrefundable, non-creditable, one-time milestone payments with respect to the
Product upon achievement of the development milestone events described below. 
  

					
	 Milestone Event
	  	Payment Amount	 
	 a) [***]
	  	 	[***	] 
	 b) [***]
	  	 	[***	] 
	 c) [***]
	  	 	[***	] 
	 d) [***]
	  	 	[***	] 
	 e) [***]
	  	 	[***	] 
	 f) [***]
	  	 	[***	] 
	 g) [***]
	  	 	[***	] 
	 h) [***]
	  	 	[***	] 
	 i) [***]
	  	 	[***	] 
	 j) [***]
	  	 	[***	] 
	 k) [***]
	  	 	[***	] 
	 l) [***]
	  	 	[***	] 
	 m) [***]
	  	 	[***	] 
	 n) [***]
	  	 	[***	] 

  
 Page 16 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 Rain shall [***] (and in any event within [***] after achievement of such milestone event)
notify Daiichi Sankyo in writing of the achievement of any such milestone event. After receipt of such notice from Rain, Daiichi Sankyo shall issue Rain an invoice for the amount of the corresponding milestone payment. Rain shall pay Daiichi Sankyo
within [***] after receipt of an invoice therefor from Daiichi Sankyo. If at the time any given milestone payment set forth in this Section 5.2 is due [***] and one or more preceding milestone payments for antecedent milestone events [***] have
not been paid, then such unpaid precedent milestone payments shall be paid at such time as well. Notwithstanding the foregoing, [***], then, milestone event a) and b) are achieved and milestone payments for milestone event a) and b) shall become
due. Rain shall notify Daiichi Sankyo in writing (i) [***] after the achievement of such milestone event (“First Notice”) and (ii) on [***] (“Second Notice”). Daiichi Sankyo shall issue Rain invoice for
milestone event b) after receiving First Notice and issue invoice for milestone event a) after receiving Second Notice, which invoices Rain shall pay Daiichi Sankyo in accordance with this Section 5.2. For clarity, Rain shall be required to pay
each development milestone payment only once, regardless of the order in which the milestone events occur. 
 5.3. Sales Milestone
Payments. As further consideration for Daiichi Sankyo’s grant of the rights and licenses to Rain hereunder, Rain will pay to Daiichi Sankyo the following payments upon the first achievement of the following levels of aggregate annual Net
Sales of all Products by Rain, its Affiliates, and its Sublicensees. If two or more sales milestone events are achieved in the same [***], then Rain shall pay to Daiichi Sankyo all of the applicable milestone payments achieved in such [***]. Rain
shall deliver written notice to Daiichi Sankyo within [***] after the end of the [***] in which a sales milestone threshold described in this Section 5.3 is achieved for the first time. Aggregate annual Net Sales of all Products shall be
calculated based on Net Sales for each Calendar Year. After receipt of such notice from Rain, Daiichi Sankyo shall issue Rain an invoice for the amount corresponding to the applicable sales milestones event. Rain shall pay Daiichi Sankyo within
[***] after receipt of an invoice therefor from Daiichi Sankyo. 
  

					
	 Milestone Event
	  	Payment Amount	 
	 Aggregate Annual Net Sales of all Products combined in the Territory in a Calendar Year equals or
exceeds [***]
	  	 	[***	] 
	 Aggregate Annual Net Sales of all Products combined in the Territory in a Calendar Year equals or
exceeds [***]
	  	 	[***	] 

  
 Page 17 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

					
	 Aggregate Annual Net Sales of all Products combined in the Territory in a Calendar Year equals or
exceeds [***]
	  	 	[***	] 
	 Aggregate Annual Net Sales of all Products combined in the Territory in a Calendar Year equals or
exceeds [***]
	  	 	[***	] 

 5.4 Royalty Payments. 

5.4.1 General. During the royalty term described in Section 5.4.3, Rain shall pay royalties to Daiichi Sankyo based
on the aggregate annual Net Sales of all Product(s) combined in the Territory by Rain, and its Affiliates and Sublicensees. Each aggregate annual Net Sales of all Product(s) in the Territory shall be calculated based on Net Sales for such Product in
each Calendar Year. The amount or royalties to be paid by Rain shall be calculated using the royalty rates set forth in Section 5.4.2. 

5.4.2. Royalty Rates. During the royalty term pursuant to Section 5.4.3, Rain will pay Daiichi Sankyo royalties of
[***] of aggregate annual Net Sales of all Product(s) sold by Rain, its Affiliates, and/or its Sublicensees. In the event that all Valid Claims of Daiichi Sankyo Patents Covering the Product are expired in a particular country, the royalty rates
shall be reduced to [***] in such country during the royalty term set forth in Section 5.4.3. 
 5.4.3. Term of
Royalty Payments. The duration of Rain’s royalty obligation will be determined on a country-by-country and Product-by-Product basis until the later of: (i) the loss of all Market Exclusivity for such Product in such country, (ii) the expiration of all Valid Claims of Daiichi Sankyo Patents that Cover the
Licensed Compound or Product in such country, or (iii) twelve (12) years from the launch of the first Product that is sold by Rain, its Affiliate, or its Sublicensee in that country. Thereafter Rain will have a fully paid up exclusive license
to the Licensed Compound and the Product(s) in that country. 
 5.5. Payments and Reports. Within [***] of the close of each [***]
during which Net Sales are recognized, Rain shall deliver a report specifying in the aggregate and on a country-by-country and monthly basis: [***]. Daiichi Sankyo shall
issue Rain an invoice for the amount of the corresponding royalty payments, which invoice Rain shall pay Daiichi Sankyo within [***] of its receipt thereof. 

5.6. Forecast Reports. Within [***] of the close of each [***], Rain shall deliver report specifying a good faith estimated Net Sales,
royalties and sales milestones to be paid to Daiichi Sankyo for each of the next [***]. Rain shall send the first such report within [***] of receiving the first Marketing Approval anywhere in the Territory, provided that such first report shall
include a forecast of Net Sales for the next [***]. 

  
 Page 18 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 5.7. Payment Method. All payments due to Daiichi Sankyo under this Agreement will be
made by bank wire transfer in immediately available funds to an account designated by Daiichi Sankyo. All payments hereunder shall be made in the legal currency of the United States, and all references to “$” or “Dollars” herein
refer to U.S. Dollars. Rain shall be responsible for paying all transfer and other fees related to completing all bank wire transfers required under this Agreement, except for the transfer fee imposed by the bank designated by Daiichi Sankyo. Within
[***] after the Effective Date, Daiichi Sankyo will provide Rain all information necessary to make such bank wire transfers. Thereafter, any change to such bank wire transfer information will be transmitted to Rain by a notice in accordance with
Section 12.11. 
 5.8. Currency Conversion. If any currency conversion is required in connection with the calculation of amounts
payable hereunder, such conversion will be made using the average of the buying and selling exchange rate for conversion of the foreign currency and U.S. Dollars, quoted for current transactions reported in [***] for the last Business Day in the
[***] to which such payment pertains. 
 5.9. Late Payments. Rain shall pay interest to Daiichi Sankyo on the aggregate amount of any
payments that are not paid on or before the date such payments are due under this Agreement at a rate per annum equal to [***], calculated on the number of days such payment is delinquent. This Section 5.9 will in no way limit any other
remedies available to Daiichi Sankyo. 
 5.10. Taxes. 

5.10.1. Withholding Taxes. If Rain is required to withhold any tax to the tax or revenue authorities in any country in
the Territory regarding any payment to Daiichi Sankyo, such amount may be deducted from the payment to be made by Rain, provided that Rain [***] notifies Daiichi Sankyo so that Daiichi Sankyo may take lawful actions to avoid or minimize such
withholding. Rain will [***] furnish Daiichi Sankyo with copies of any tax certificate or other documentation evidencing such withholding, as necessary to enable Daiichi Sankyo to support a claim, if permissible, for income tax credit in respect of
any amount so withheld. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any agreement or treaty in effect from time to time. On or shortly after the Effective Date, Daiichi Sankyo
shall deliver to Rain a properly completed Internal Revenue Service (“IRS”) Form W-8BEN-E or other applicable IRS
Form W-8. 
 5.10.2. Value Added Taxes. All payments due to Daiichi
Sankyo from Rain pursuant to this Agreement shall be paid exclusive of any value added tax, which will be paid by Rain upon receipt of a valid value added tax invoice. For clarity, the upfront, milestone and royalty payments under this Agreement are
not subject to such value added tax in Japan as long as Rain’s entity in Japan does not make the payment. 
 5.11. Records. Rain
will keep, and will cause its Affiliates and its Sublicensees to keep, complete, true and accurate books of accounts and records, in compliance with applicable laws 

  
 Page 19 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
and the terms and conditions of this Agreement, sufficient to determine and establish the calculation of Net Sales and royalties payable under this Agreement for a period of [***] after the year
in which the sale of the Product(s) generating the same occurred. 
 5.12. Inspection of Records. At the request of Daiichi Sankyo,
Rain and its Affiliates will permit an independent certified public accountant appointed by Daiichi Sankyo and reasonably acceptable to Rain, to inspect the books and records described in Section 5.11 (except that Rain will directly audit its
Sublicensees upon request, no more frequently than [***]); provided that such inspection shall be at reasonable times and upon reasonable notice and not more often than [***], and the same records may not be audited more than once except it is
necessary to be audited due to new fact that were not recognized in the first audit. Such accountant will enter into a customary confidentiality agreement with Rain. Any inspection conducted under this Section 5.12 will be at Daiichi
Sankyo’s expense, unless such inspection reveals any underpayment of [***] or more of any amount due to Daiichi Sankyo during the audited period, in which case the full costs of such inspection will be paid by Rain. Any amount found to be due
to Daiichi Sankyo, will be paid by Rain within [***] with interest on the underpayment at the rate specified in Section 5.9 from the date such payment was originally due until paid. 

 

	6.	 Intellectual Property. 

6.1. Ownership of Licensed Intellectual Property. Subject to the licenses granted in Article 2 of this Agreement, each Party will retain
all right, title and interest in and to, and ownership of, all inventions, Know-How, Patents and other intellectual property conceived, discovered, developed, reduced to practice, or otherwise made solely by
or on behalf of such Party (or its Affiliates or its or their Sublicensees). Subject to the licenses and other rights granted herein, as between the Parties, each Party will own an equal, undivided interest in any and all Joint Know-How and Joint Patents. Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, each Party will be entitled to practice, license and assign its interest
in the Joint Technology without the duty of accounting or seeking consent from the other Party, and where consent is required, such consent is hereby given. Inventorship and ownership rights in Inventions and other
Know-How created, developed, conceived and/or reduced to practice after the Effective Date under this Agreement will be determined under the intellectual property laws of the United States of America,
irrespective of where such creation, development, conception, discovery, development or making occurs. 
 6.2. Filing, Prosecution and
Maintenance. 
 6.2.1. Daiichi Sankyo Patents. 

6.2.1.1. Rain Responsibility. Subject to Section 6.2.1.2, using counsel of its choice, Rain shall be responsible,
at its sole expense, for preparing, filing, prosecuting, and maintaining the Daiichi Sankyo Patents, including preparing and filing requests for patent term extensions, supplemental protection certificates, pediatric exclusivity, or similar

  
 Page 20 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
protections that extend the term of such Daiichi Sankyo Patents. Rain shall also be solely responsible for defending the Daiichi Sankyo Patents from any challenges to their validity or
enforceability, including responding to patent office communications or office actions, oppositions, reissue or reexamination proceedings, or interferences, brought by any Third Party, whether before a patent authority or judicial body. Rain shall
consult with Daiichi Sankyo and keep it reasonably informed regarding actions it takes in connection with preparing, filing, prosecuting, maintaining and defending Daiichi Sankyo Patents. Daiichi Sankyo shall, upon request, provide reasonable
support to Rain, including signing documents necessary for Rain to fulfill its obligations under this Section 6.2.1.1. If Rain decides that it will no longer prosecute or maintain a Daiichi Sankyo Patent in a certain country, it will give
Daiichi Sankyo reasonable notice of its decision, which will include sufficient time prior to the expiration or termination of all relevant deadlines for taking necessary actions to preserve the rights in such Daiichi Sankyo Patent. Daiichi Sankyo
will have the right, but not the obligation, to assume control over and continue prosecuting and maintaining any Daiichi Sankyo Patent that Rain ceases to prosecute and maintain. 

6.2.1.2. Daiichi Sankyo Responsibility. Using counsel of its choice, Daiichi Sankyo shall, at its own expense, be
responsible for further prosecuting and maintaining the Patent that is described as [***]. Daiichi Sankyo shall also be solely responsible for defending such [***] from any challenges to their validity or enforceability, including responding to
patent office communications or office actions, oppositions, reissue or reexamination proceedings, or interferences, brought by any Third Party, whether before a patent authority or judicial body. Daiichi Sankyo shall provide Rain a reasonable
opportunity to review and comment on material submissions and correspondence regarding to the prosecution, maintaining or defending of [***], provided Daiichi Sankyo has final decision-making authority over such matters. If Daiichi Sankyo decides
that it will not continue to prosecute or maintain [***], it will notify Rain of its decision and, if requested, take all necessary steps to allow Rain to assume responsibility for prosecuting and maintaining such [***]. 

6.2.2. Rain Patents and Joint Patents. Rain will be responsible, at its sole expense, for preparing, filing,
prosecuting, and maintaining Patents that cover its own inventions (“Rain Patents”), and Joint Patents that are useful to research, develop, manufacture or commercialize the Licensed Compound or Product. Rain will also be solely
responsible for defending the Rain Patents and Joint Patents from any challenges to their validity or enforceability, including responding to patent office communications or office actions, oppositions, reissue or reexamination proceedings, or
interferences, brought by any Third Party, whether before a patent authority or judicial body. Rain 

  
 Page 21 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
will consult with Daiichi Sankyo and keep it reasonably informed regarding actions it takes in connection with preparing, filing, prosecuting, maintaining and defending Joint Patents. If Rain, in
its sole discretion, decides that it will no longer prosecute or maintain a Joint Patent, it will give Daiichi Sankyo reasonable notice of its decision, which will include sufficient time prior to the expiration or termination of all relevant
deadlines for taking necessary actions to preserve the rights in such Joint Patent, and will allow Daiichi Sankyo to assume control over and continue prosecuting and maintaining such Joint Patent. If requested by Daiichi Sankyo, Rain will assign its
rights in such Joint Patent to Daiichi Sankyo or its designee. 
 6.2.3. Regulatory Exclusivity. If Rain decides to
seek regulatory and/or data exclusivity for a Product, Rain will be responsible, at its sole expense, for preparing and filing such requests with the applicable Regulatory Authority. Daiichi Sankyo will, upon request, provide reasonable support to
Rain in preparing and filing such requests to Regulatory Authority in [***] and [***] at Rain’s expense. 
 6.3. Defense of
Infringement Claims by Third Parties. 
 6.3.1. Liability. If a Third Party files or threatens to file an
infringement claim against either Party or both Parties related to the manufacture, use, offer for sale, sale, importation or exportation of a Licensed Compound or Product in any country within the Territory, Rain will defend such claim at its own
expense and will be solely responsible for all damages awarded to the Third Party plaintiff, whether as a result of a court order or an agreement to settle. Daiichi Sankyo will assist and cooperate with Rain in defending such claim(s) upon
reasonable requests and at Rain’s expense. Notwithstanding anything to the contrary herein, this Section 6.3.1 and Section 6.3.2 are subject to Article 9. 

6.3.2. Control. Rain will solely control the defense of infringement claim(s) brought against either Party or both
Parties by Third Parties arising from the manufacture, use, offer for sale, sale, importation or exportation of a Licensed Compound or Product in any country within the Territory, including the right to control settlement of such claim(s), provided
that Rain may not agree to terms in the settlement that will adversely affect Daiichi Sankyo’s rights or interests unless Daiichi Sankyo has given prior written consent, which will not be unreasonably withheld or delayed. Notwithstanding
Rain’s right to control the defense of claim(s) of infringement, if Daiichi Sankyo is named as a defendant, it will have the right to participate in such case, including by engaging separate counsel, at its sole expense. Without affecting or
limiting Rain’s right to control the defense of infringement claims by Third Parties, if Daiichi Sankyo elects to engage separate counsel, the Parties shall cooperate in defending and/or settling such claims. 

6.4. Enforcement Actions against Third Parties. 

  
 Page 22 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 6.4.1. Notification. If either Party learns of any infringement,
unauthorized use, misappropriation or ownership claim, or threatened infringement of any Daiichi Sankyo Technology and/or Joint Technology by a Third Party with respect to the Licensed Compound or Product anywhere within the Territory, including the
filing of an ANDA under Section 505(j) of the U.S. Federal Food, Drug, and Cosmetic Act (“FD&C Act”) or an application under Section 505(b)(2) of the FD&C Act naming a Product as a reference listed drug and
including a certification under Section 505(j)(2)(A)(vii)(IV) or 505(b)(2)(A)(iv), respectively, or any equivalent filing outside of the U.S. (“Hatch-Waxman Case”), such Party will [***] notify the other Party in writing and
will [***] provide the other Party with available evidence of such infringement or other such claim, provided that in the case of Hatch-Waxman Case, the Party receiving such notice shall notify the other Party within [***] of such receipt and
provide the paragraph (IV) notice letter (or the applicable equivalent thereof). 
 6.4.2. Control. 

6.4.2.1. Rain Responsibility. Subject to Section 6.4.2.2, Rain will have the first right, but not the obligation,
to institute an infringement suit, initiate administrative proceedings, or take other appropriate action against a Third Party for any alleged infringement of any Daiichi Sankyo Patents or Joint Patents anywhere within the Territory, including a
defense or counterclaim in connection with any Third Party infringement claim, at its sole cost and expense, using counsel of its own choice. If Rain does not secure actual cessation of the offending activities, or institute an infringement
proceeding or other administrative proceeding against an offending Third Party, Rain will notify Daiichi Sankyo of such circumstances as soon as reasonably practicable, but in any case no later than [***] (or such shorter period as necessary to
preserve rights, in the case of Hatch-Waxman Case, within [***] after such receipt) of learning of such infringement or threatened infringement. Upon receiving such notice, Daiichi Sankyo will have the right, but not the obligation, at its sole
discretion, to take appropriate actions in the name of either Party or both Parties. Each Party will execute all necessary and proper documents, and take such actions as are necessary and appropriate to allow the other Party to institute and
prosecute such infringement actions and will otherwise cooperate in instituting and prosecuting such actions (including, without limitation, consenting to being named as a nominal party thereto). 

6.4.2.2. Daiichi Sankyo Responsibility. Daiichi Sankyo will have the first right, but not the obligation, to institute
an infringement suit, initiate administrative proceedings, or take other appropriate action against a Third Party for any alleged infringement of [***] anywhere within the Territory, including a defense or counterclaim in connection with any Third
Party infringement claim, at its sole cost and expense, using counsel of its 

  
 Page 23 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
own choice. Daiichi Sankyo shall provide Rain a reasonable opportunity to review and comment on material submissions and correspondence regarding the infringement of [***], provided Daiichi
Sankyo has final decision-making authority over such matters. If Daiichi Sankyo does not secure actual cessation of the offending activities, or institute an infringement proceeding or other administrative proceeding against an offending Third
Party, Daiichi Sankyo will notify Rain of such circumstances as soon as reasonably practicable, but in any case no later than [***] (or such shorter period as necessary to preserve rights, in the case of Hatch-Waxman Case, within [***] after such
receipt) of learning of such infringement or threatened infringement. Upon receiving such notice, Rain will have the right, but not the obligation, at its sole discretion, to take appropriate actions in the name of either Party or both Parties. Each
Party will execute all necessary and proper documents, and take such actions as are necessary and appropriate to allow the other Party to institute and prosecute such infringement actions and will otherwise cooperate in instituting and prosecuting
such actions (including, without limitation, consenting to being named as a nominal party thereto). 
 6.4.3.
Expenses. The costs and expenses of any such enforcement actions against Third Parties (including fees of attorneys and other professionals) will be paid by the Party instituting the action, or, if the Parties elect to cooperate in
instituting and maintaining such action, such costs and expenses will be borne by the Parties in such proportions as they may agree in writing. Any damages paid by Third Parties as a result of such an enforcement action (whether by way of settlement
or otherwise) will be applied first to reimburse both Parties for all costs and expenses incurred. If such funds are not sufficient to reimburse all expenses of both Parties, all funds will be divided on a pro rata basis in the same proportion as
the costs and expenses incurred. If any funds remain after all expenses of both Parties have been reimbursed, such excess funds will be divided on a pro rata basis in the same proportion as the costs and expenses incurred. 

6.5. Trademarks. Rain will have the right and the responsibility, at its expense, to choose the brand(s) under which the Licensed
Product will be marketed in the Territory. Rain will, at its expense, own all trademarks used in the marketing of the Licensed Product in the Territory. 
  

	7.	 Confidentiality. 

7.1. Confidential Information. Except to the extent expressly authorized by this Article 7 or otherwise agreed in a writing signed by
both Parties, each Party (the “Receiving Party”) shall, during and for [***] after the Term of this Agreement, keep confidential and not publish or otherwise disclose and not use for any purpose other than as explicitly provided for
in this Agreement (including performing its obligations and exercising its rights) any confidential and 

  
 Page 24 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
proprietary information or materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise) that are disclosed or provided to it by the other
Party or an Affiliate of the other Party (each a “Disclosing Party”) or otherwise received or accessed by a Receiving Party, its Affiliates, or its Sublicensees from the Disclosing Party in the course of performing its obligations
under this Agreement including, but not limited to, any trade secrets, Know-How, Product specifications, formulae, processes, techniques and information relating to the Disclosing Party’s past, present
and future marketing, financial, and research and development activities for any product of the Disclosing Party and the pricing thereof (collectively, “Confidential Information”). Confidential Information of each Party includes
(a) any information disclosed by such Party under the Bilateral Confidential Disclosure Agreement between the Parties dated January 27, 2020 and as amended on May 22, 2020 and June 16, 2020, and (b) the terms and conditions
of this Agreement. 
 7.2. Exceptions. Notwithstanding the foregoing, Confidential Information does not include information or
materials to the extent that it can be established by the Receiving Party that such information or material: 
 7.2.1. is
already lawfully known to the Receiving Party, other than under an obligation of confidentiality at the time of disclosure by the Disclosing Party as evidenced by written records kept in the ordinary course of business, or other documentary proof of
actual use by the Receiving Party; 
 7.2.2. is generally available to the public or otherwise part of the public domain at
the time of its disclosure to the Receiving Party; 
 7.2.3. becomes generally available to the public or otherwise part of
the public domain after its disclosure to the Receiving Party and other than through any act or omission of the Receiving Party, its Affiliates, or its Sublicensees in violation of this Agreement; 

7.2.4. is independently developed by the Receiving Party as demonstrated by documented evidence prepared contemporaneously with
such independent development; or 
 7.2.5. is lawfully disclosed to the Receiving Party, other than under an obligation of
confidentiality, by a Third Party who had no obligation not to disclose such information to others. 
 7.3. Authorized Disclosure.
Notwithstanding Section 7.1, the Receiving Party may disclose Confidential Information of the Disclosing Party: 

7.3.1. to its respective directors, officers, employees, consultants and advisors, and to the directors, officers, employees,
consultants and advisors of such Receiving Party’s Affiliates, Sublicensees, or potential investors or sublicensees, who 

  
 Page 25 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
have a need to know such Confidential Information in connection with the activities or transactions contemplated in this Agreement and have an obligation to treat such Confidential Information as
confidential under terms no less restrictive than those set forth herein (provided that the term of such obligations may be shorter but no less than [***]); 

7.3.2. in its publicly filed financial statements or other public statements pursuant to applicable laws, regulations, and
stock exchange rules or otherwise disclosed pursuant to applicable law; provided, that: (a) the terms of this Agreement are redacted to the greatest extent possible; and (b) such Receiving Party provides the Disclosing Party with a copy of
the proposed text of such statements or disclosure (including any exhibits containing this Agreement) sufficiently in advance of the scheduled release or publication thereof to afford the Disclosing Party a reasonable opportunity to review and
comment on the proposed text (including redacted versions of this Agreement). 
 7.3.3. to governmental authorities to
facilitate the issuance of Marketing Approvals for a Product; provided that reasonable measures are taken to assure confidential treatment of such information; 

7.3.4. to the extent such disclosure is reasonably necessary in filing or prosecuting patent, copyright and trademark
applications, prosecuting or defending litigation, complying with applicable governmental regulations, conducting preclinical activities or clinical trials and marketing a Product; 

7.3.5. to Third Parties in connection with a Receiving Party’s efforts to secure financing or enter into strategic
partnerships or other transactions (including mergers or acquisitions), provided such information is disclosed only on a need-to-know basis and under confidentiality
provisions at least as stringent as those in this Agreement (provided that the terms of such obligations may be shorter but no less than [***]); 

7.3.6. that is required to be disclosed in response to a valid order by a court or other governmental body and provided that
the Receiving Party provides the Disclosing Party with prompt notice of such requirement so that the Disclosing Party may seek a protective order or other appropriate remedy, then the Receiving Party may furnish only that portion of the Confidential
Information which the Receiving Party is legally compelled to disclose; 
 7.3.7. that is required to be disclosed in
connection with any legal or regulatory requirements or obligations, including SEC filings or Regulatory Filings, provided that the Receiving Party offers reasonable cooperation to the Disclosing Party in an attempt, as may be permitted and
appropriate, to redact or seek confidential treatment of sensitive Confidential Information; or 

  
 Page 26 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 7.3.8. if the Receiving Party is Daiichi Sankyo, to Third Parties who are
listed in Exhibit J for the purpose of complying with the obligation of the agreements with such Third Parties, provided such information is disclosed under confidentiality provisions at least as stringent as those in this Agreement (provided that
the terms of such obligations may be shorter but no less than [***]). 
 7.4. Publications by Rain. If Rain, its Affiliates, and/or
its Sublicensees, but excluding its clinical investigators, proposes a publication related to the Licensed Compound or Product that includes Confidential Information of Daiichi Sankyo, Rain will first submit an early draft of such publication to
Daiichi Sankyo, whether they are to be presented orally or in written form, at least [***] prior to submission for publication or presentation. Daiichi Sankyo will review such proposed publication/presentation in order to avoid unauthorized
disclosure of its Confidential Information and to preserve the patentability of inventions. Based on the review, as soon as reasonably possible, but no more than [***] from receipt of the advance copy of the proposed publication, Daiichi Sankyo may:

 7.4.1. Request that Rain delete such Confidential Information of Daiichi Sankyo contained in the proposed publication, in
which case Rain, its Affiliate, or its Sublicensee shall delete such Confidential Information from its proposed publication; and/or 

7.4.2. Inform Rain that its proposed publication could be expected to have a material adverse effect on any Patent, Know-How, compound or product of Daiichi Sankyo, in which case Rain, its Affiliate, or its Sublicensee shall delay such proposed publication for an additional [***] to permit the timely preparation and first filing
of patent application(s) covering the information involved. 
 7.5. Publication by Daiichi Sankyo. Daiichi Sankyo may publish or
otherwise disclose the data and results of (i) Daiichi Sankyo’s pre-clinical and clinical studies conducted prior to the Effective Date or (ii) any collaboration between Daiichi Sankyo and
academia that exists as of the Effective Date relating to the Licensed Compound provided that it will receive prior written consent from Rain which consent shall not be unreasonably withheld, conditioned or delayed; provided that Daiichi Sankyo and
Rain shall discuss the inclusion of reference to Rain in each such publication or disclosure and agree to an expression in advance in writing. Notwithstanding the foregoing, Rain and Daiichi Sankyo will jointly decide the timing of a publication or
presentation of the results of the [***] Continuing Clinical Trial pursuant to Section 7.4. Written consent of Rain will not be required to publish any information that has already been publicly disclosed either prior to the Effective Date or
after the Effective Date through no fault of Daiichi Sankyo or otherwise not in violation of this Agreement. Daiichi Sankyo shall give Rain at least [***] to review the draft contents of the abstract, the poster or the slide deck before it is
presented at the conferences and the draft contents of the journal article before it is submitted for publication, shall 

  
 Page 27 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
consult with Rain with respect thereto, and shall incorporate any reasonable comments of Rain with respect thereto. Daiichi Sankyo will provide the draft in the language which it was drafted and
Daiichi Sankyo shall not be obligated to translate such draft. Notwithstanding the foregoing, Rain will notify Daiichi Sankyo within such [***] period if the proposed publication could be expected to have a material adverse effect on any Patent, Know-How, compound or product of Rain (including any Licensed Compound or Product or Daiichi Sankyo Technology), in which case Daiichi Sankyo will delay such proposed publication for an additional [***] to permit
the timely preparation and first filing of patent application(s) covering the information involved. 
 7.6. Publication by Academia.
Any academia, who is collaborated with Daiichi Sankyo under a particular agreement relating to the Licensed Compound as of the Effective Date, may publish or otherwise disclose the study design, the data and results of
pre-clinical and clinical studies conducted under such agreement. Daiichi Sankyo shall give Rain at least [***] to review and comment on the draft contents of the abstract, the poster or the slide deck before
such academia is presented at the conferences and the draft contents of the journal article before such academia is submitted for publication, provided that Rain acknowledges and agrees that the review period may be shorter, depending on the
circumstances and demands of the academia. Daiichi Sankyo shall incorporate any reasonable comments of Rain with respect thereto. Daiichi Sankyo will provide the draft in the language which it was drafted and Daiichi Sankyo shall not be obligated to
translate such draft. 
 7.7. Press Releases. Neither Party may issue any press release including any Confidential Information
disclosed by the other Party or the other Party’s name without such Party’s review and prior written approval, except as required under Applicable Laws. Rain may issue any press release related to the Licensed Compound which is not
including Daiichi Sankyo’s Confidential Information and/or company name provided it shall submit the final draft of such press release to Daiichi Sankyo at least [***] (or such shorter period as necessary in the event of legally required
disclosures) prior to publication. 
 7.8. Restrictions on Use. During and for [***] after the Term, the Receiving Party shall not
use, and shall ensure that its Affiliates, and require that its Sublicensees do not use any Confidential Information disclosed to it by a Disclosing Party or otherwise received or accessed from the Disclosing Party in the course of performing its
obligations under this Agreement for any purpose including press release other than as expressly provided herein without the prior written approval of the Disclosing Party. For clarity, this restriction will not apply to information that is covered
by one or more of the exceptions described in Section 7.2 of this Agreement. 
 7.9. Use of Name. Except as otherwise provided
herein, neither Party has any right, express or implied, to use the name or other designation of the other Party or any other trade name, trademark or logo of the other Party in any manner or for any purpose in connection with this Agreement without
the prior written approval of the other Party, except for use in connection with notices or filings required by law, rule, or regulation. 

  
 Page 28 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

	8.	 Representations, Warranties and Covenants. 

8.1. Representations and Warranties of Both Parties. Each Party represents and warrants to the other, as of the Effective Date, that:

 8.1.1. it is duly organized and validly existing under the laws of its jurisdiction of incorporation, and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 
 8.1.2. it is duly
authorized to execute and deliver this Agreement and to perform its obligations hereunder and that it has the right to grant to the other Party the licenses granted pursuant to this Agreement, and the person or persons executing this Agreement on
its behalf has been duly authorized to do so by all requisite corporate action; 
 8.1.3. this Agreement is legally binding
upon it and, upon execution by the other Party, shall be enforceable in accordance with its terms except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or other laws affecting the enforcement of creditors’
rights generally and subject to the general principles of equity (regardless of whether enforcement is sought in a court of law or equity); 

8.1.4. the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument
or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any governmental agency or Regulatory Authority having jurisdiction over it; 

8.1.5. it has not granted any right to any Third Party that would conflict with the rights granted to the other Party
hereunder; 
 8.1.6. it has not been debarred under the Generic Drug Enforcement Act of 1992 (21 U.S.C. §301 et seq.),
is not under investigation for debarment action, has not been disqualified as an investigator pursuant to 21 C.F.R. §312.70, does not have a disqualification hearing pending and is not currently employing (and in the case of Daiichi Sankyo, did
not previously employ in connection with its activities with respect to any Licensed Compound or Product) any person or entity that has been so debarred or disqualified to perform any of its obligations under this Agreement. It shall [***] notify
the other Party if it is so debarred or disqualified and shall terminate any so debarred or disqualified individual’s or entity’s participation in the performance of any of its obligations under this Agreement [***] upon its awareness of
such debarment or disqualification; and 

  
 Page 29 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 8.1.7. it is not aware of any action, suit or inquiry or investigation
instituted by any person or governmental agency that questions or threatens the validity of this Agreement. 
 8.2. Additional
Representations, Warranties and Covenants of Daiichi Sankyo. Daiichi Sankyo warrants, represents and covenants to Rain as follows: 

8.2.1. As of the Effective Date, Daiichi Sankyo owns or Control all of the Daiichi Sankyo Technology in existence on the
Effective Date, free and clear of all encumbrances, and has the right to grant the licenses with respect thereto as purported to be granted herein; Exhibit B is an accurate listing by serial number, filing date, country and status of all patents and
patent applications owned or controlled by Daiichi Sankyo or its Affiliates as of the Effective Date that claim or cover any Licensed Compound or Product; with respect to any Daiichi Sankyo’s obligation with respect to Licensed Compound or
Product under certain agreements existing as of the Effective Date as between Daiichi Sankyo and Third Party (“Upstream Agreement”), all Upstream Agreements are in full force and effect as of the Effective Date, Daiichi Sankyo is
not in breach thereof, and Daiichi Sankyo has not received any written notice of default or termination of any Upstream Agreement; Daiichi Sankyo covenants that during the Term, (i) it shall use all reasonable efforts to satisfy all of its
obligations under, and take all reasonable steps necessary to maintain in full force and effect, each of the Upstream Agreements, (ii) it shall not assign, amend, restate or terminate in whole or in part, or otherwise modify, any of the
Upstream Agreements without the prior written consent of Rain, to the extent that any such amendment, restatement or modification affects Rain’s rights or obligations under this Agreement, and (iii) it shall provide Rain with prompt notice
of any claim of a breach under any of the Upstream Agreements or notice of termination of any of the Upstream Agreements, to the extent relevant to the rights or obligations of Rain under this Agreement; 

8.2.2. As of the Effective Date, to the knowledge of Daiichi Sankyo, the Daiichi Sankyo Patents: (a) that are issued as of
the Effective Date are, valid and in full force and effect, and there is no fact or circumstance known to Daiichi Sankyo that would cause Daiichi Sankyo to reasonably conclude that any of the issued patents in the Daiichi Sankyo Patents is invalid
or unenforceable, and (b) are not the subject of any interference or opposition proceedings; 
 8.2.3. As of the
Effective Date, there is no pending, and to the knowledge of Daiichi Sankyo, there is no threatened, action, suit, proceeding or claim by a Third Party challenging the ownership rights in, or the validity or scope of the Daiichi Sankyo Patents, or
otherwise related to the Licensed Compound or Daiichi Sankyo Technology; 

  
 Page 30 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 8.2.4. As of the Effective Date, to the knowledge of Daiichi Sankyo, none of
the Daiichi Sankyo Know-How was obtained by Daiichi Sankyo in violation of any contractual or fiduciary obligation to which it or any of its employees or staff are or were bound, or by the misappropriation of
a trade secret of any Third Party; 
 8.2.5. Unless specifically disclosed to Rain to be otherwise prior to the Effective
Date, as of the Effective Date, there is no pending or threatened action, suit, proceeding or claim that was brought to Daiichi Sankyo’s attention by a Third Party in writing asserting that the use or practice of any of Daiichi Sankyo’s Know-How infringes or otherwise is violating any patents, trade secret or other proprietary right of any Third Party; 

8.2.6. [***], as of the Effective Date, to the knowledge of Daiichi Sankyo, the research, development and commercialization of
the Licensed Compound and Product (in the forms it exists as of or prior to the Effective Date) do not infringe or otherwise violate any patents, trade secrets or other proprietary rights of any Third Party in the Territory; 

8.2.7. Disclosure Schedule attached hereto as Exhibit J sets forth a true and complete listing of all Third Parties with which
Daiichi Sankyo has an agreement as of the Effective Date related to the Licensed Compound, including academic and other research collaborators; 

8.2.8. As of the Effective Date, no government or other Third Party funding was used in the development of any inventions in
the Daiichi Sankyo Patents; 
 8.2.9. Daiichi Sankyo and its Affiliates have conducted the research and development of the
Licensed Compound and Product in compliance with all Applicable Laws, including as applicable GLP, GCP, and GMP and any applicable anti-corruption or anti-bribery laws or regulations; and 

8.2.10. Neither Daiichi Sankyo nor its Affiliates, nor, to Daiichi Sankyo’s knowledge, any of its or their respective
directors, officers, employees or agents has (a) committed an act, (b) made a statement or (c) failed to act or make statement, in any case ((a), (b) or (c)), that (i) would be or create an untrue statement of material fact or
fraudulent statement to the FDA or any other Regulatory Authority with respect to the development and manufacture of any Licensed Compound or Product or (ii) could reasonably be expected to provide a basis for the FDA or any other Regulatory
Authority to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities”, set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or any analogous laws or policies, with
respect to the development and manufacture of any Licensed Compound or Product. 

  
 Page 31 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 8.3. Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH
PARTY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND UNDER THIS AGREEMENT (INCLUDING WITH RESPECT TO ANY MATERIALS PROVIDED UNDER THIS AGREEMENT), EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY,
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF PATENT CLAIMS, WHETHER ISSUED OR PENDING. 
 8.4. Limitation
of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON FOR INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES,
ARISING OUT OF THIS AGREEMENT, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STATUTE, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES. THE FOREGOING LIMITATION OF LIABILITY, HOWEVER,
SHALL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER ARTICLE 9 OR DAMAGES AVAILABLE FOR BREACH OF ARTICLE 7. 
  

	9.	 Indemnification. 

9.1. Indemnification by Daiichi Sankyo. Daiichi Sankyo will defend, hold harmless and indemnify (collectively,
“Indemnify”) Rain and its Affiliates, and its and their respective agents, directors, contractors, representatives, officers and employees (collectively, “Rain Indemnitees”) from and against any liability or
expense, including without limitation reasonable legal expenses and attorneys’ fees, (collectively, “Losses”) resulting from suits, claims, actions and demands, in each case brought by a Third Party (each, a
“Third-Party Claim”) to the extent arising from (a) a breach of any of Daiichi Sankyo’s representations, warranties or covenants or other obligations pursuant to this Agreement, or any negligence or willful misconduct by
any Daiichi Sankyo Indemnitees in the exercise of any of Daiichi Sankyo’s rights or the performance of any of Daiichi Sankyo’s obligations under this Agreement, or (b) any research, development, sale, offer for sale or importation of
any Licensed Compound or Product in the Territory by Daiichi Sankyo, its Affiliates, and/or its licensees (other than Rain), or (c) the marketing or sales activities of Daiichi Sankyo, its Affiliates, and/or its licensees (other than Rain) in
the Territory after the effective date of termination of this Agreement. Daiichi Sankyo’s obligation to Indemnify the Rain Indemnitees pursuant to this Section 9.1 shall not apply to the extent that any such Losses arise from the
negligence, willful misconduct or wrongful acts or omissions of any Rain Indemnitee or Rain’s breach of this Agreement. 

  
 Page 32 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 9.2. Indemnification by Rain. Rain will Indemnify Daiichi Sankyo and its Affiliates,
and its and their respective agents, directors, contractors, representatives, officers and employees (collectively, “Daiichi Sankyo Indemnitees”) from and against any and all Losses resulting from Third-Party Claims to the extent
arising from (a) a breach of any of Rain’s representations, warranties or covenants or other obligations pursuant to this Agreement, any violation of applicable law, or any negligence or willful misconduct by any Rain Indemnitees in the
exercise of any of Rain’s rights or the performance of any of Rain’s obligations under this Agreement, or (b) any research, development, sale, offer for sale or importation of any Licensed Compound or Product in the Territory by Rain,
its Affiliates, and/or its Sublicensees, or (c) the marketing or sales activities of Rain, its Affiliates, and/or its Sublicensees in the Territory. Rain’s obligation to Indemnify the Daiichi Sankyo Indemnitees pursuant to this
Section 9.2 shall not apply to the extent that any such Losses arise from the negligence, willful misconduct or wrongful acts or omissions of any Daiichi Sankyo Indemnitee or Daiichi Sankyo’s breach of this Agreement. 

9.3. Procedure. To be eligible to be indemnified hereunder, any Rain Indemnitee under Section 9.1 or Daiichi Sankyo Indemnitee
under Section 9.2, as the case may be (an “Indemnitee”) seeking indemnification, must provide the indemnifying Party with prompt notice of the Third-Party Claim giving rise to the claimed indemnification obligation and must
assign the exclusive ability to defend or settle any such claim to the indemnifying Party; provided, however, that the indemnifying Party may not enter into any settlement that admits fault, wrongdoing or damages on the part of the Indemnitee
without such Indemnitee’s written consent, such consent not to be unreasonably withheld or delayed. The Indemnitee will cooperate with reasonable requests from the indemnifying Party, at the indemnifying Party’s expense, and will have the
right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party. Without affecting or limiting the indemnifying Party’s right to control the defense of
the Third Party Claim, if the Indemnitee elects to engage separate counsel, the Parties shall cooperate in defending and/or settling such claims. 

9.4. Complete Indemnification. Indemnification under this Article 9 will include the reasonable costs and expenses of the Indemnitee
relating to legal fees and expenses and damages awarded to the Indemnitee in connection with enforcement of Sections 9.1 and 9.2. 
 9.5.
Allocation. If a claim is based in part on an indemnified claim, as described in Sections 9.1 and 9.2, and in part on a non-indemnified claim, or is based in part on a claim described in
Section 9.1 and in part on a claim described in Section 9.2, any payments and reasonable attorney fees incurred in connection with such claims will be apportioned between the Parties in accordance with the degree of fault attributable to
each Party. 
 9.6. Insurance. During the Term and for [***] thereafter, each Party will maintain a policy of insurance at levels
sufficient to support its indemnification obligations, but in any case such insurance must provide adequate coverage for clinical trials liability, products liability, worker’s compensation, employer’s liability, and comprehensive general
liability and consistent with the normal business practices of prudent pharmaceutical companies of similar size and scope. Upon a Party’s request, the other Party shall provide evidence of such insurance. Each Party shall

  
 Page 33 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
notify the other Party of any cancellation, lapse or material change in the applicable insurance. Notwithstanding the foregoing, Daiichi Sankyo may satisfy the requirements of this
Section 9.6 through a commercially reasonable program of self-insurance. 
  

	10.	 Term and Termination. 

10.1. Term. This Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this
Article 10, will continue in full force and effect until Rain and all of its Affiliates and Sublicensees cease all development and commercial activity related to all Licensed Compound and Products throughout the Territory (the
“Term”). 
 10.2. Termination by Daiichi Sankyo. 

10.2.1. Daiichi Sankyo may terminate this Agreement as a whole or on a country-by-country basis, without prejudice to any other remedies available to it at law or in equity, if Rain, its Affiliate, or its Sublicensee commits a material breach of this Agreement that, in the case
of a material breach capable of remedy, has not been remedied within [***] of receiving a notice from Daiichi Sankyo identifying the breach and requiring its remedy, or if such material breach cannot be cured within [***], if Rain does not commence
and diligently continue actions to cure such breach during such [***]; provided that if Rain disputes [***] the existence or materiality of a breach specified in a notice provided by Daiichi Sankyo within such [***] period, then Daiichi Sankyo shall
not have the right to terminate this Agreement under this Section 10.2.1 unless and until the arbitrators, in accordance with Section 11.2, have determined that Rain has materially breached the Agreement and that Rain fails to cure such
breach within [***] following such arbitrators’ decision. During the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective
obligations hereunder. The Parties acknowledge that non-payment of sums due from Rain hereunder will be considered a material breach of this Agreement. Rain may cure any material breach by a Sublicensee by
terminating the sublicense agreement with such Sublicensee within [***] of receiving a notice from Daiichi Sankyo identifying the breach. 

10.2.2. To the extent permitted by law, Daiichi Sankyo may terminate this Agreement immediately upon written notice to Rain if:
(a) Rain makes or seeks to make or arrange an assignment for the benefit of creditors; (b) proceedings in voluntary bankruptcy are initiated by or on behalf of Rain or proceedings in involuntary bankruptcy are initiated against Rain (and,
in the case of any such involuntary proceeding, not dismissed within [***]); or (c) a receiver or trustee of Rain’s property is appointed and not discharged within [***]. 

10.2.3. Daiichi Sankyo may terminate this Agreement immediately upon written notice if Rain, its Affiliate, or its Sublicensees
initiates or joins any challenge, whether in a court of law or in an administrative proceeding, to the validity 

  
 Page 34 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
or enforceability of a Daiichi Sankyo Patent; provided that if such challenge is by a Sublicensee, Daiichi Sankyo will not have the right to terminate this Agreement under this
Section 10.2.3 if Rain terminates such Sublicensee’s sublicense to the Daiichi Sankyo Technology within [***] after receipt of Daiichi Sankyo’s notice. This Section 10.2.3 will not apply to (a) any such challenge that is
first made in defense of a claim of patent infringement brought by Daiichi Sankyo, (b) any reexamination, reissue or similar proceeding intended to improve the validity, enforceability or scope of a Daiichi Sankyo Patent, or (c) complying
with any applicable laws or regulations (including court order), including responding to compulsory discovery subpoenas or other requests for information in a judicial or arbitration proceeding. 

10.3. Termination by Rain. 

10.3.1. Rain may terminate this Agreement, without prejudice to any other remedies available to it at law or in equity, if
Daiichi Sankyo commits a material breach of this Agreement that, in the case of a material breach capable of remedy, has not been remedied within [***] of receiving a notice from Rain identifying the breach and requiring its remedy, or if such
material breach cannot be cured within such [***] period, if Daiichi Sankyo does not commence and diligently continue actions to cure such breach during such [***]; provided that (a) if the material breach relates to one or more but not all
countries in the Territory, Rain may terminate this Agreement only with respect to the affected country(ies), and (b) if Daiichi Sankyo disputes in good faith the existence or materiality of a breach specified in a notice provided by Rain
within such [***] period, then Rain shall not have the right to terminate this Agreement under this Section 10.3.1 unless and until the arbitrators, in accordance with Section 11.2, have determined that Daiichi Sankyo has materially
breached the Agreement and that Daiichi Sankyo fails to cure such breach within [***] following such arbitrators’ decision. During the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the
Parties shall continue to perform all of their respective obligations hereunder. 
 10.3.2. Rain may terminate this Agreement
on a country-by-country basis (or region-by-region basis) or may terminate this Agreement
in its entirety for bona fide material concerns regarding the (a) lack of safety for human use arising from toxicity of the Licensed Compound or Product(s), (b) lack of efficacy of the Licensed Compound or Product(s), or (c) adverse
economic impact to Rain of continued development of the Licensed Product upon six (6) months prior written notice to Daiichi Sankyo. The notice under this Section 10.3.2 will specify in detail the basis for such termination, including a
reasonable description of such material concern(s). Prior to the written notice of termination, Rain shall discuss [***] such material concerns with Daiichi Sankyo for [***]. Termination by Rain of its activities under this Agreement pursuant in all
of the countries/regions within the Territory shall constitute termination of this Agreement in its entirety pursuant to this Section 10.3.2. 

  
 Page 35 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 10.4. Accrued Obligations/Survival. Expiration or termination of this Agreement for
any reason does not release either Party from any obligation or liability which, at the time of such expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination.
Section 3.6.3 (Confidential Information), Section 5.9 (Late Payments), Section 5.11 (Records), Section 5.12 (Inspection of Records), Section 6.1 (Ownership of Licensed Intellectual Property), Section 6.2.2 (Rain Patents
and Joint Patents), Article 7 (Confidentiality), Section 8.3 (Disclaimer of Warranties), Section 8.4 (Limitation of Liability), Article 9 (Indemnification), this Section 10.4 (Accrued Obligations/Survival), Section 10.5 (Effects
of Terminations), Article 11 (Dispute Resolution), Section 12.9 (Governing Law), Section 12.10 (Submission to Jurisdiction) and Section 12.11 (Notices) shall survive expiration or termination of this Agreement for any reason. 

10.5. Effects of Terminations. 

10.5.1. If Rain terminates this Agreement in its entirety or with respect to a particular country in the Territory (each
affected country being a “Terminated Country”) pursuant to Section 10.3.2 or Section 3.6.2, in each case: 
 a)
If there are any ongoing clinical trials in such Terminated Country being conducted by or on behalf of Rain, its Affiliate, or its Sublicensee, at the time the notice of termination is sent, Rain will, as of the actual termination date: (i) [***]
transfer, free of charge, to Daiichi Sankyo or its designee some or all of such clinical trials and the activities related to or supporting such trials; or (ii) terminate such clinical trials; in each case upon request from Daiichi Sankyo and
at Daiichi Sankyo’s sole discretion. Notwithstanding the foregoing, if the clinical trials in the Terminated Country are required or useful for Regulatory Filings or permitted activities with respect to the Product outside the Terminated
Country, then Rain will, upon sending written notice of its decision to terminate its activities in the Terminated Country, have the option of completing such clinical trials. 

b) If requested by Daiichi Sankyo, Rain will: (i) [***] transfer to Daiichi Sankyo or its designee copies of all data, reports, records,
materials that relate to the Product in such Terminated Country, (ii) provide Daiichi Sankyo or its designee with all information necessary or desirable to cross-reference or assume responsibility for any Regulatory Filings, as the case may be,
in Rain’s name with respect to the Product, in such Terminated Country, and (iii) return to Daiichi Sankyo all relevant records and materials in Rain’s possession or control containing Confidential Information of Daiichi Sankyo
relating solely to the Licensed Compound and the Product in such Terminated Country, provided that Rain may keep one copy of such Confidential Information for archival purposes or as may be necessary or useful in connection with Rain’s
activities under this Agreement outside of the Terminated Country. If Rain elects to terminate this Agreement in its entirety, within [***] of such termination, Rain shall also provide Daiichi Sankyo with copies of all preclinical and clinical data
(including investigator 

  
 Page 36 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
reports, both preliminary and final, statistical analyses, expert opinions and reports, safety and other electronic databases) and, subject to Section 10.5.1(c), other Know-How Controlled by Rain that is licensed to Daiichi Sankyo under Section 10.5.1(c). 
 c) If
requested by Daiichi Sankyo after receiving a notice of termination with regard to a Terminated Country under Section 10.3.2, Rain shall grant Daiichi Sankyo an exclusive, irrevocable, fully paid up license, with the right to sublicense, under
any Patents and Know-How that are Controlled by Rain that are actually being used by Rain at the time of termination in connection with the Product for Daiichi Sankyo to make, have made, use, sell, offer for
sale, import and export the Licensed Compound or the Product in such Terminated Country. 
 d) If requested by Daiichi Sankyo, Rain shall
grant and shall cause to be executed to Daiichi Sankyo an exclusive, irrevocable, fully paid up license, with the right to sublicense, to use any trademarks specific to the Product in such Terminated Country. Upon termination of this Agreement, at
the request of Daiichi Sankyo, Rain shall assign and shall cause to be assigned to Daiichi Sankyo all rights in and to any trademarks owned by Rain specific to the Product(s). It is understood that such assignment will not include the Rain name or
any company trademark, trade name, or logo of Rain itself. 
 e) The licenses granted to Rain under Section 2.1 shall terminate in the
Terminated Country or throughout the Territory if this Agreement is terminated in its entirety. 
 f) If requested by Daiichi Sankyo, Rain
will assign all sublicense agreements granted by Rain under this Agreement in the Terminated Country to Daiichi Sankyo or its designee to the extent permitted under those agreements and not adversely affecting Rain’s activities outside of the
Terminated Country. If Daiichi Sankyo does not request assignment of such sublicense agreements, then such sublicense agreements shall terminate upon termination of Rain’s rights with respect to the Licensed Compound and the Product in the
Terminated Country. 
 g) If Rain elects to terminate this Agreement in its entirety, each Party shall return all relevant records and
materials in its possession or control containing the other Party’s Confidential Information, provided that each Party may keep one copy of such Confidential Information for archival purposes only. 

10.5.2. If Rain terminates this Agreement in its entirety or with respect to any Terminated Country pursuant to
Section 10.3.1, the licenses granted to Rain under Section 2.1 shall terminate in the Terminated Country or throughout the Territory if this Agreement is terminated in its entirety. In the event that Rain has the right to terminate this
Agreement pursuant to Section 10.3.1, in lieu of terminating this Agreement Rain may, at its option, elect to keep this Agreement in effect and seek damages pursuant to Section 11.2. In such event, the arbitrators will be authorized to
award an equitable reduction in payments under this Agreement to reflect the diminution of value of the Daiichi Sankyo Technology, if any, resulting from Daiichi Sankyo’s material breach of this Agreement. 

  
 Page 37 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 10.5.3. If Daiichi Sankyo terminates this Agreement in its entirety or with
respect to any Terminated Country pursuant to Section 10.2: 
 a) If there are any ongoing clinical trials with respect to Product
being conducted by or on behalf of Rain, its Affiliates, or its Sublicensees in the Terminated Country at the time of notice of termination, Rain will, free of charge, as of the termination date, [***] transfer some or all of such clinical trials
and the activities related to or supporting such trials to Daiichi Sankyo or its designee, or terminate such clinical trials, in each case as requested by Daiichi Sankyo, or complete such clinical trials on terms as mutually agreed by both Parties.
Notwithstanding the foregoing, if the clinical trials in the Terminated Country are required or useful for Regulatory Filings or permitted activities with respect to the Product outside the Terminated Country, then Rain will, upon sending written
notice of its decision to terminate its activities in the Terminated Country, have the option of completing such clinical trials. 
 b) If
requested by Daiichi Sankyo, Rain shall, free of charge, [***] assign and transfer to Daiichi Sankyo or its designee all Regulatory Filings for Product that are held by Rain or its Affiliates in the Terminated Country, and shall take such actions
and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights under the Regulatory Filings to Daiichi Sankyo or its designee. If applicable law prevents or delays the transfer of ownership of a
Regulatory Filing, Rain shall grant Daiichi Sankyo or its designee a permanent, exclusive and irrevocable right of access and reference to such Regulatory Filing in the Terminated Country for a Product, and will fully cooperate to make the benefits
of such Regulatory Filings available to Daiichi Sankyo or its designee. At the request of Daiichi Sankyo, within [***] of such termination, Rain shall provide, free of charge, to Daiichi Sankyo or its designee copies of all such Regulatory Filings
and of all preclinical and clinical data (including investigator reports, both preliminary and final, statistical analyses, expert opinions and reports, safety and other electronic databases) and other
Know-How Controlled by Rain that are necessary for Daiichi Sankyo to submit an application for Marketing Approval for a Product in the Terminated Country. 

c) Notwithstanding other provisions in this Section 10.5.2, (i) if Daiichi Sankyo terminates this Agreement in its entirety or with
respect to a Terminated Country pursuant to Section 10.2.1 or Section 10.2.3, upon Daiichi Sankyo’s request, Rain shall grant Daiichi Sankyo an exclusive, irrevocable, fully paid up license, with the right to sublicense, under any
Patents and Know-How that are Controlled by Rain that are actually being used by Rain at the time of termination in connection with the Product to make, have made, use, sell, offer for sale, import and export
the Licensed Compounds or the Product in the Terminated Country; and (ii) if Daiichi Sankyo terminates this Agreement in its entirety pursuant to Section 10.2.2, upon Daiichi Sankyo’s request, Rain shall engage in good faith
negotiation regarding the commercial terms and consideration for a separate exclusive royalty-bearing license, with the right to sublicense, under any Patents and Know-how that are Controlled by Rain that are
actually being used by Rain at the time of termination in connection with the Product for Daiichi Sankyo to make, have made, use, sell, offer for sale, import and export the Licensed Compound or the Product(s). 

  
 Page 38 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 d) Notwithstanding other provisions in this Section 10.5.2, (i) if Daiichi Sankyo
terminates this Agreement in its entirety or with respect to a Terminated Country pursuant to Section 10.2.1 or Section 10.2.3, upon Daiichi Sankyo’s request, Rain shall grant Daiichi Sankyo or its designee an exclusive, irrevocable,
fully paid up license, with the right to sublicense, to use any Trademarks specific to the Product in the Terminated Country. It is understood that such assignment shall not include the Rain name or any trademark, trade name, or logo of Rain itself;
and (ii) if Daiichi Sankyo terminates this Agreement in its entirety pursuant to Section 10.2.2, upon Daiichi Sankyo’s request, Rain shall engage in good faith negotiation regarding the commercial terms and consideration for an
exclusive royalty-bearing license, with the right to sublicense for Daiichi Sankyo or it designee to use any Trademarks specific to the Product. It is understood that such license will not include the Rain name or any trademark, trade name, or logo
of Rain itself. 
 e) If requested by any Sublicensee with rights to a Terminated Country, the sublicense granted to such Sublicensee in
such Terminated Country will survive as a direct license from Daiichi Sankyo, and Daiichi Sankyo will enter into an agreement with such Sublicensee for such license, provided that (a) such Sublicensee is in compliance with the terms of its
sublicense agreement and (b) Daiichi Sankyo shall have no obligations under such sublicense agreement beyond the obligations expressly set forth in this Agreement. If the Sublicensee does not request such direct license, then such sublicense
agreement will terminate upon termination of Rain’s rights with respect to the Licensed Compound and the Product in the Terminated Country. 

f) If requested by Daiichi Sankyo, Rain shall fully cooperate with Daiichi Sankyo or its designee to facilitate a smooth, orderly and prompt
transition of the development and commercialization of the Product to Daiichi Sankyo or its designee in the Terminated Country upon termination. Without limiting the foregoing, and if applicable, Rain shall [***] provide Daiichi Sankyo copies of
customer lists, customer data and other customer information relating to the Product in the Terminated Country, which Daiichi Sankyo shall have the right to use and disclose in connection with its development and commercialization of the Product in
the Terminated Country. 
 g) If requested by Daiichi Sankyo upon termination of this Agreement in its entirety, Rain shall complete, or
shall cause its Affiliate, to complete, all work-in-process to manufacture finished Product and will transfer any quantities of the Licensed Compound and finished
Product (including work-in-process when finished) in its or its Affiliates’ possession to Daiichi Sankyo or its designee, for which Daiichi Sankyo shall reimburse
Rain [***] of its (or its Affiliate’s) cost of goods within [***] of such transfer. Daiichi Sankyo will pay all shipping, insurance and customs charges associates with such transfer. 

h) If Rain, or its Affiliate is manufacturing the Product at the time the termination of this Agreement in its entirety becomes effective,
then Rain, or its Affiliate shall 

  
 Page 39 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
continue to manufacture such Product for Daiichi Sankyo, at [***] of the cost of goods plus a reasonable profit, from the date of notice of such termination until such time as Daiichi Sankyo is
able to secure an acceptable alternative commercial manufacturing source, which period shall not exceed [***]. If requested by Daiichi Sankyo, Rain shall engage in good faith negotiation regarding the commercial terms and consideration for,
effective upon termination of this Agreement, a separate agreement to transfer the technology necessary to manufacture the Product for sale in the Territory. 

i) Upon receiving instructions from the other Party upon termination of this Agreement in its entirety, each Party shall return, and shall
cause its Affiliates to return, to the other Party or destroy all relevant records and materials in its possession or control containing Confidential Information of the other Party, provided that each Party may keep one copy of such Confidential
Information for archival purposes only. 
 10.5.4. Each Party acknowledges that the other Party’s obligations following
any termination are subject to, and may be limited by, all applicable laws, rules, regulations, or contractual restrictions. 
  

	11.	 Dispute Resolution. 

11.1. Between the Parties. In the event of a dispute between the Parties arising out of or related to the terms of this Agreement,
either Party may request that the Parties engage in good faith discussions to resolve such dispute. Within [***] of such request, each Party will appoint an appropriate representative of such Party to engage in discussions to resolve the dispute in
a mutually acceptable manner. Such representative will have a reasonable level of expertise in the subject matter of the dispute and possess the requisite authority to resolve the dispute. If such representatives are unable to resolve the dispute
within [***], either Party may provide a written request to submit the dispute for discussions between Executive Officers appointed by the respective Chief Executive Officers of each Party. If the Executive Officers are unable to resolve the dispute
within [***] after referral, either Party may provide a written request to refer the dispute for arbitration. 
 11.2. Arbitration.
If a dispute has not been resolved by negotiation as provided in Section 11.1, such disputes arising out of or in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by
[***] arbitrators. Each Party shall nominate [***] arbitrator and the [***] party-nominated arbitrators shall nominate the [***] arbitrator, who shall serve as the presiding arbitrator, within [***] after the second arbitrator’s appointment.
The seat, or legal place, of the arbitration shall be New York, New York. The language of the arbitration shall be English. The arbitrators will render their award in writing and, unless all Parties agree otherwise, will include an explanation in
reasonable detail of the reasons for their award. Any arbitration award may be entered in and enforced by a court in accordance with Section 12.10. Should such courts for any reason lack jurisdiction, any court with jurisdiction may act in the
same fashion. The existence, nature and results of, as well as any documents relating to, any arbitration shall be treated as Confidential Information by the 

  
 Page 40 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
Parties and the arbitrators, except (i) to the extent that disclosure may be required of a Party to fulfill a legal duty, protect or pursue a legal right, or enforce or challenge an award in
bona fide legal proceedings before a state court or other judicial authority, (ii) with the consent of all Parties, (iii) where needed for the preparation or presentation of a claim or defense in this arbitration, (iv) where such
information is already in the public domain other than as a result of a breach of this clause, or (v) by order of the arbitrators upon application of a Party. Each Party shall have the right to seek injunctive or other equitable relief from a
court of competent jurisdiction pursuant to Section 12.10 that may be necessary to avoid irreparable harm, maintain the status quo or preserve the subject matter of the arbitration, and such request shall not be deemed incompatible with, or a
waiver of, this agreement to arbitrate. The arbitrators will, in rendering their decision, apply the substantive law of New York, without regard to its conflict of laws provisions. The decision and/or award rendered by the arbitrators will be final
and non-appealable (except for an alleged act of corruption or fraud on the part of the arbitrators). 
  

	12.	 Miscellaneous Provisions. 

12.1. Relationship of the Parties. Rain and Daiichi Sankyo agree that the relationship between them established by this Agreement is
that of independent contractors. The Parties further agree that this Agreement does not, is not intended to, and should not be construed to establish an employment, agency, partnership, joint venture, or any other relationship between them. Except
as may be specifically provided herein, neither Party has any right, power or authority, nor may they represent themselves as having any right, power or authority, to assume, create or incur any expense, liability or obligation, express or implied,
on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose. 
 12.2. No Third-Party
Beneficiaries. No person or entity other than Rain, Daiichi Sankyo and their respective Affiliates, permitted assignees and sublicensees may be deemed an intended beneficiary or have any right to enforce any obligation of this Agreement. 

12.3. Assignments. Neither Party may assign this Agreement or any of its rights or obligations hereunder to its Affiliate or Third
Party without the prior written consent of the other Party except that either Party may assign this Agreement without such consent in connection with the acquisition of all or substantially all of the assets of the assigning Party upon [***] prior
written notice to the other Party. No assignment or transfer of this Agreement is valid or effective unless and until the assignee/transferee agrees in writing to be bound by the provisions of this Agreement. The terms and conditions of this
Agreement will be binding on and inure to the benefit of the successors and permitted assigns of the Parties. Any attempted assignment not in accordance with the terms of this Agreement will be void. 

12.4. Performance by Affiliates. Either Party may perform its obligations under this Agreement through one or more Affiliates without
prior approval of the other Party. The Party will nonetheless remain solely responsible for the performance of its obligations under this Agreement by its Affiliate(s) and for any breach of the terms of this Agreement by its Affiliate(s). 

  
 Page 41 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 12.5. No Implied Waivers; Rights Cumulative. The failure of either Party to assert a
right hereunder or to insist upon compliance with any term or condition of this Agreement does not constitute a waiver of that right or excuse a similar subsequent failure to perform such term or condition. Any term or condition of this Agreement
may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver is effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. No waiver by any
Party of any term or condition of this Agreement, in any one or more instances, may be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. Except as expressly set forth in this
Agreement, all rights and remedies available to a Party, whether under this Agreement or afforded by law or otherwise, are cumulative and not in the alternative to any other rights or remedies that may be available to such Party. 

12.6. Severability. If any provision of this Agreement is held to be invalid, illegal or unenforceable under law in any jurisdiction,
the Parties will negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement will remain in full force and effect in such
jurisdiction and will be liberally construed in order to carry out the intentions of the Parties as nearly as may be possible. A holding of invalidity, illegality or unenforceability of a provision in one jurisdiction will not affect the validity,
legality or enforceability of such provision in any other jurisdiction. 
 12.7. Entire Agreement; Amendments. This Agreement,
together with all Exhibits, constitutes the entire agreement between the Parties with respect to the subject matter hereof, and supersedes all previous arrangements, whether written or oral, with respect to the subject matter contained herein,
including the Bilateral Confidential Disclosure Agreement between the Parties dated January 27, 2020, and as amended on May 22, 2020 and June 16, 2020, which are hereby terminated in its entirety. Any amendment or modification to this
Agreement must be made in a writing signed by both Parties. 
 12.8. Force Majeure. Neither Party will be liable to the other Party
for failure or delay in performing of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by; epidemic, pandemic, earthquake, riot, civil commotion, rebellion; insurrection, invasion, fire, acts
of God, war, terrorist acts, strike, storm, flood, or governmental acts or restriction, or other cause that is beyond the reasonable control of the affected Party. The Party affected by such force majeure must provide the other Party with full
particulars thereof (including its best estimate of the likely extent and duration of the interference with its activities) as soon as it becomes aware of the same, but in no event more than [***] after becoming aware of it. The affected Party will
use Commercially Reasonable Efforts to overcome the difficulties created by the force majeure and to resume performance of its obligations as soon as practicable. In such event, the Parties will meet [***] to determine an equitable solution to
minimize or accommodate the effects of any such event, including the possibility of terminating this Agreement. 
 12.9. Governing
Law. This Agreement shall be governed by, and any disputes, claims or controversies in connection with this Agreement, including any question regarding its 

  
 Page 42 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 
formation, existence, validity, enforceability, performance, interpretation or termination, shall be resolved in accordance with, the laws of the State of New York without regard to its conflict
of laws rules. 
 12.10. Submission to Jurisdiction. Solely for the purposes set forth in Section 11.2, each Party submits to
the jurisdiction of the United States District Court for the Southern District of New York and the Supreme Court of the State of New York, New York County (collectively, the “Courts”), and agrees not to raise any objection at any time to
the laying or maintaining of the venue of any such action, suit or proceeding in any of such Courts, irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives the
right to object, with respect to such action, suit or other proceeding, that such Court does not have any jurisdiction over such Party. Each Party may serve on the other Party by sending or delivering a copy of the process to the Party to be served
at the address and in the manner provided for giving notices, as provided in Section 12.11. Each Party hereto waives its right to trial of any issue by jury. Nothing in this Section 12.10, however, shall affect the right of any Party to
serve legal process in any other manner permitted by law. 
 12.11. Notices. Any notice, request, delivery, approval or consent
required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by e-mail (receipt verified) or by express
courier service (signature required) or [***] after it was sent by registered letter, return receipt requested (or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within [***] after such
mailing, to the Party to which it is directed at its address or e-mail address shown below or such other address or e-mail address as such Party shall have last given by
notice to the other Party. 
 If to Daiichi Sankyo, addressed to: 

Daiichi Sankyo Company, Limited 

5-1 Nihonbashi-honcho 3-Chome 

Chuo-ku, Tokyo 103-8426 Japan 

Attention: Vice President, Business Development & Licensing 

Telephone: [***] 
 Email: [***]

  
 Page 43 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 If to Rain, addressed to: 

Rain Therapeutics Inc. 
 8000
Jarvis Avenue, Suite 204 
 Newark, CA 94560 

USA 
 Attention: [***] 

Telephone: [***] 
 Email: [***]

 With a copy to: Avanish Vellanki, CEO 

12.12. No Strict Construction. This Agreement has been prepared jointly by the Parties and should not be strictly construed against
either Party. 
 12.13. Interpretation. The captions and headings in this Agreement are for convenience only and are to be of no
force or effect in construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Sections or Exhibits mean those particular Sections and Exhibits to this Agreement and references to this
Agreement include all attachments hereto. The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine,
feminine and neuter forms. Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words “include” or “including” shall be construed as incorporating, also, “but not limited to” or
“without limitation”; (b) the word “day” or “year” means a calendar day or year unless otherwise specified; (c) the word “notice” means notice in writing (whether or not specifically stated); (d) the
words “hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement (including any Exhibits); (e) the word “or” shall be construed as the inclusive meaning identified with the phrase
“and/or”; (f) words using the singular or plural number also include the plural or singular number, respectively; (g) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed
to include the then-current amendments thereto or any replacement law, rule or regulation thereof; and (h) the word “country” shall be construed as including administrative region (e.g., Hong Kong) and other quasi-national region as
appropriate from the context. 
 12.14. Counterparts. This Agreement may be executed in any number of counterparts, each of which
will be deemed an original, and all of which together, will constitute one and the same. 

  
 Page 44 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 Page 45 of 46 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION

  

 IN WITNESS WHEREOF, Rain and Daiichi Sankyo have caused this Agreement to be executed by
their duly authorized representatives as of the date first written above. 
  

									
	DAIICHI SANKYO COMPANY, LIMITED	 		 	RAIN THERAPEUTICS INC.
					
	Signature:	 	 /s/ Sunao Manabe
	 		 	Signature:	 	 /s/ Avanish Vellanki

			
	Printed Name: Sunao Manabe	 		 	Printed Name: Avanish Vellanki
			
	Title: President and Chief Executive Officer	 		 	Title: Chairman & Chief Executive Officer

  
 Page 46 of 46EX-10.11

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 Exhibit 10.11 

This Intellectual Property License Agreement (this “Agreement”) includes this Signature Page and all of the attached Terms and
Conditions and Exhibits, as applicable. This Agreement is between Drexel University, a Pennsylvania non-profit corporation (“Drexel”), and Rain Therapeutics Inc., a Delaware corporation
(“Company”). This Agreement is being signed on July 30, 2020 (the “Execution Date”). This Agreement will become effective on July 30, 2020 (the “Effective Date”). 

Intending to be legally bound, each party has caused this Agreement to be executed by its duly authorized representative. 

 

									
	RAIN THERAPEUTICS INC.	 		 	DREXEL UNIVERSITY
					
	By:	 	 /s/ Avanish Vellanki
	 		 	By:	 	 /s/ Robert B. McGrath

	Name:	 	Avanish Vellanki	 		 	Name:	 	Robert B. McGrath
	Title:	 	Chief Executive Officer	 		 	Title:	 	Senior Associate Vice Provost

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 TERMS AND CONDITIONS 

 

	1.	 BACKGROUND. 

1.1. Background. Drexel owns certain intellectual property developed by [***] of Drexel’s College of Medicine relating to RAD52 inhibitors for the
treatment of cancer. Drexel also owns certain Patent Rights and Technical Information relating to such intellectual property. Company desires to obtain an exclusive license under the Patent Rights and a nonexclusive license to the Technical
Information to exploit the intellectual property. Company also desires to fund further research by [***] under the Sponsored Research Agreement. Drexel has determined that the exploitation of the intellectual property by Company is in the best
interest of Drexel and is consistent with its educational and research missions and goals. 
  

	2.	 DEFINITIONS 

2.1. Glossary. All capitalized terms used in these Terms and Conditions but not otherwise defined in the Signature Page will have the meaning ascribed
to them in the Glossary of Terms attached as Exhibit A. 
  

	3.	 LICENSE 

3.1. License Grant. Drexel grants to Company a non-transferable (except in connection with a permitted
assignment under Section 15.5) worldwide license, under (a) the Patent Rights, to make, have made, use, import, offer for sale and sell Licensed Products in the Field of Use during the Term and (b) the Technical Information, to make,
have made, use, import, offer for sale and sell Licensed Products in the Field of Use during the Term. The License is exclusive with respect to the Patent Rights and non-exclusive with respect to the Technical
Information. The License includes the right to sublicense after the first anniversary of the Effective Date as permitted by this Agreement. No other rights or licenses are granted by Drexel. Any intellectual property created or conceived as a result
of the performance of the Sponsored Research Agreement between Drexel and Company being entered into simultaneously with this Agreement will be governed by the terms of the Sponsored Research Agreement. 

3.2. Reservation of Rights by Drexel. Drexel reserves the right to use, and to permit other non-commercial
entities to use, the Patent Rights for educational and research purposes, but excluding research sponsored by a commercial entity and excluding the use of Licensed Products in clinical trials. Notwithstanding the foregoing, a marketed Licensed
Product can be used in an investigator-initiated clinical trial. Drexel will use reasonable efforts to notify Company of the permission it expressly grants to such permitted entity to use the Patent Rights or conduct a clinical trial of a Licensed
Product. 
 3.3. U.S. Government Rights. The parties acknowledge that the United States government retains rights in intellectual property funded
under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products, which result from such
intellectual property and are sold in the United States, must be substantially manufactured in the United States. 

  
 1 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 3.4. Sublicense Conditions. The Company’s right to sublicense granted by Drexel under the License
is subject to each of the following conditions: 
 (a) In each Sublicense Agreement, Company will prohibit Sublicensee and each permitted further
sublicensee from further sublicensing the License (other than to its affiliate) and require Sublicensee to comply with the applicable terms and conditions of this Agreement; provided that such Sublicensee will have the right to grant further
sublicenses (i) in countries outside [***] in which such Sublicensee would customarily grant sublicenses in accordance with its reasonable business judgment and (ii) in [***] with Drexel’s prior written consent. 

(b) Within [***] after Company enters into a Sublicense Agreement or a permitted Company Sublicensee enters into a further Sublicense Agreement, Company will
deliver to Drexel a complete and accurate copy of the entire Sublicense Agreement written in the English language; provided that Company may redact any proprietary information of the Sublicensee but not the economic terms of the Sublicense Agreement
or the description of the intellectual property that is licensed to the Sublicensee provided such proprietary information is contained in an exhibit to the Sublicense Agreement. Company represents, warrants, and covenants that Company shall not
redact any such information necessary for Drexel to confirm compliance with this Agreement or payments owed to Drexel hereunder, nor use such information redaction as a reason for not complying with this Agreement. Drexel’s receipt of the
Sublicense Agreement, however, will not constitute (i) a waiver of any right of Drexel or obligation of Company under this Agreement or (ii) an approval of the Sublicense Agreement or any sublicense of the License granted thereunder. 

(c) In the event that Company causes or experiences a Trigger Event, all payments due to Company from its Affiliates or Sublicensees under each Sublicense
Agreement will, upon notice from Drexel to such Affiliate or Sublicensee, become payable directly to Drexel for the account of Company. Upon receipt of any such funds, Drexel will remit to Company within [***] the amount by which such payments
exceed the amounts owed by Company to Drexel. 
 (d) Company’s execution of a Sublicense Agreement will not relieve Company of any of its obligations
under this Agreement. Company is primarily liable to Drexel for any act or omission of an Affiliate or Sublicensee that would be a breach of this Agreement if performed or omitted by Company, and Company will be deemed to be in breach of this
Agreement as a result of such act or omission. 
 3.5. Delivery of Technical Information. Within [***] after the Effective Date, Drexel shall deliver
to Company all Technical Information requested by Company in Exhibits F and G in a form reasonably agreed by the parties. Company hereby acknowledges that Drexel has met its obligation under this Section 3.5, the “Delivery of Technical
Information”. 
 3.6. Improvements. 
 (a) The
parties will form an advisory committee, consisting of the Investigator, relevant personnel working in his laboratory, and appropriate members of Company to discuss the Improvements and related data generated by the parties and the parties’
strategy and goals for research related to the Improvements. The committee will meet quarterly in person or by 

  
 2 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 
telephone and will not have any decision-making authority under this Agreement. Company will be responsible for preparing meeting minutes and written action items [***] after each committee
meeting. 
 (b) To the extent there are no third party obligations, for a period of five (5) years from the Effective Date Drexel hereby grants to
Company the first option to license Drexel’s rights in each Improvement (including each Improvement made solely by Drexel and each Improvement made jointly by Drexel and Company) (the “Option”), related patent rights and/or
related know-how for [***] after Company has been notified of the existence of each such Improvement. Within [***] after Drexel receives written disclosure of any Improvement, Drexel will notify Company in
writing of such Improvement, furnishing Company a copy of any invention disclosure and any related patent applications on a confidential basis. Drexel will take reasonable steps, consistent with its customary and usual practices, to ensure that any
such notification to Company is made reasonably before the occurrence of any disclosure or other activity that might impair any patentability of such Improvement. Within [***] after receipt of such notice from Drexel, by written notice to Drexel
Company may exercise the option to license such Improvement, related patent rights and/or related know-how, and Drexel and Company shall negotiate in good faith to determine the terms of any such license
agreement. The parties agree that the terms of such license agreement will be determined, in part, by taking into account comparable transactions in the marketplace, including but not limited to any comparable transactions between Company and
Drexel, including this Agreement, and will provide for reasonable milestone and royalty payments for products subject to such license agreement and this Agreement. If Company and Drexel fail to execute a license agreement within [***] after Company
has been notified of such Improvement, Drexel shall be free to license the Improvement to any party upon such terms as Drexel deems appropriate without any further obligation to Company. For clarity, any license to the
know-how will be non-exclusive. The parties expressly agree that Drexel shall solely own all right, title and interest in and to each Improvement, including any related patent rights and know-how, made jointly by Drexel and Company. Company does hereby agree to have all Company inventors who made an inventive contribution to such Improvements assign to Drexel all right, title and interest in all
such inventive contributions. 
  

	4.	 DILIGENCE 

4.1. Development Plan. Company will deliver to Drexel a copy of the initial Development Plan within [***] after the Effective Date. The purpose of the
Development Plan is (a) to demonstrate Company’s capability to bring the Patent Rights to commercialization, (b) to project the timeline for completing the necessary tasks, and (c) to measure Company’s progress against the
projections. Thereafter, starting in [***], Company will deliver to Drexel [***] updated Development Plan no later than [***] of each [***] during the Term. 

4.2. Company’s Efforts. Company will use commercially reasonable efforts to develop, commercialize, market and sell Licensed Products in a manner
consistent with the Development Plan; provided that Drexel agrees that any sales projections in the Development Plan are for information purposes only, and any failure to meet such sales projections will not be deemed a breach of this
Section 4.2. 

  
 3 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 4.3. Diligence Events. The Company will use commercially reasonable efforts to achieve each of
the Diligence Events by the applicable completion date listed in the table below for the first Licensed Product: 
  

			
	 DILIGENCE EVENT
	  	 COMPLETION DATE

	 [***]
	  	as set forth in [***]
	 [***]
	  	[***] after Effective Date
	 Receipt of IND approval for a Licensed Product
	  	4 years after Effective Date
	 [***]
	  	[***] after Effective Date
	 [***]
	  	[***] after Effective Date
	 [***]
	  	[***] after Effective Date
	 [***]
	  	[***] after Effective Date
	 [***]
	  	[***] after Effective Date

 provided that with respect to the foregoing completion dates, to the extent any delay in meeting such completion dates is due
to bona fide unforeseen discovery or development obstacles, and while Company is diligently advancing the program, such completion dates will be extended upon mutual agreement of the parties, which agreement will not be unreasonably withheld. 

 

	5.	 FEES AND ROYALTIES 

5.1. License Initiation Fee. In partial consideration of the License and the Option, Company will pay to Drexel a
one-time, non-refundable, non-creditable license initiation fee of $20,000 payable in [***] after the Effective Date and [***],
[***] and [***] after the Effective Date. 
 5.2. License Maintenance Fees. In partial consideration of the License, commencing upon filing of the
first IND for a Licensed Product, Company will pay to Drexel the license maintenance fee of $15,000 on each anniversary of the Effective Date until the first Sale of the first Licensed Product. Such license maintenance fee shall be creditable
against any milestone payments or sublicense income received during the [***] period after the applicable anniversary of the Effective Date. 
 5.3.
Milestone Payments. In partial consideration of the License, Company will pay to Drexel the applicable one-time (per Licensed Product) milestone payment listed in the table below after the first
achievement of each milestone event for each Licensed Product; provided that (i) two Licensed Products will be considered different only if they contain different compounds, and (ii) if a Licensed Products fails in development and a backup
Licensed Product is developed in the same indication, the backup Licensed Product will not trigger milestone payments already paid for the failed Licensed Product. Company will provide Drexel with written notice within [***] after achieving each
milestone. Notwithstanding the foregoing, if Company receives any Sublicense Income on account of the achievement of any milestone event listed below, Company will pay Drexel the greater of the amount listed below and the amount due under
Section 5.6, but not both. As used in the table below, an “indication” means an individual, separate and distinct disease or medical condition for which [***]. 
  

					
	 MILESTONE
	  	PAYMENT	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

  
 4 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

					
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

 5.4. Earned Royalties. In partial consideration of the License, Company will pay to Drexel for each Quarter during the
term of this Agreement a royalty equal to [***] of Net Sales of a Licensed Product for the Quarter. The [***] royalty rate may be reduced on a Licensed
Product-by-Licensed Product, quarter-by-quarter and territory-by-territory basis as follows: (i) in the event Company pays royalties to Drexel and one or more third parties or to Drexel under one or more separate agreements in connection with licenses to
make or sell a Licensed Product and the aggregate royalty rate exceeds [***], Drexel’s royalty rate under this Agreement can be reduced pro rata with the third party or other Drexel royalty rates according to the following formula: reduced
Drexel royalty rate under this Agreement = [***], where A is the initial Drexel royalty rate under this Agreement, B is the aggregate royalty rate of the other license agreements, provided, however, that in no event shall Drexel’s royalty under
this Agreement be below [***] of Net Sales for such Licensed Product; (ii) in the event all Valid Claims of the patents and patent applications under the Patent Rights that cover the sale of the applicable Licensed Product in the applicable
country expire or become abandoned, the royalty payable to Drexel shall be reduced to [***] of Net Sales for the applicable Licensed Product; (iii) in the event the sale of a Licensed Product in a particular country is not covered by the Patent
Rights, the royalty payable to Drexel shall be [***] of Net Sales of such Licensed Product in such country; and (iv) on a territory-by-territory basis, in the event
a Generic Equivalent of a Licensed Product enters the market, the royalty payable to Drexel for Sales of such Licensed Product in such territory shall be reduced to [***]. For clarity, in the event the sale of a Licensed Product in a particular
country is not covered by the Patent Rights in such country but such Licensed Product is covered by the Patent Rights in at least one other country, the provisions of item (iii) of this Section 5.4 shall not apply and the royalty payable
to Drexel shall be [***] of Net Sales, subject to reduction provisions of items (i), (ii) and (iv) of this Section 5.4. 
 5.5. Minimum
Royalties. In partial consideration of the License, Company will pay to Drexel the amount, if any, by which $6,250 exceeds Company’s actual earned royalties under Section 5.4 for each Quarter after the first Sale of a Licensed Product.

 5.6. Sublicense Fees. In partial consideration of the License, subject to Section 5.3, Company will pay to Drexel a sublicense fee of [***]
of the Sublicense Income received by Company from Sublicensees during each [***]. Following [***], Company will pay to Drexel a sublicense fee of [***] of the Sublicense Income received by Company from Sublicensees during each [***]. For clarity,
the change from [***] to [***] is based on when the sublicense was granted and the sublicense fee percentage shall remain at that level for the applicable sublicense throughout the term of this agreement. 

5.7. Transaction Fee. In partial consideration of the License, Company will pay to Drexel, within [***] after receipt of a reasonably detailed invoice
from Drexel issued on the Execution Date, a one-time, non-refundable, non-creditable transaction fee equal to the actual amount
of Drexel’s licensing and legal expenses in connection with this Agreement, the Term Sheet and the Sponsored Research Agreement. 

  
 5 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

	6.	 REPORTS AND PAYMENTS 

6.1. Royalty Reports. Within [***] after the end of each Quarter following the first Sale, Company will deliver to Drexel a report, certified by the
chief financial officer of Company, detailing the calculation of all royalties, fees and other payments due to Drexel for such Quarter. The report will include, at a minimum, the following information for the Quarter, each listed by product, by
country: [***]. Each royalty report will be substantially in the form of the sample report attached as Exhibit B. 
 6.2. Payments. Company will pay
all royalties, fees and other payments due to Drexel under Sections 5.3, 5.4, 5.5 and 5.6 within [***] after the end of the Quarter in which the royalties, fees or other payments accrued. 

6.3. Records. Company will maintain, and will cause its Affiliates and Sublicensees to maintain, complete and accurate books, records and related
background information to verify Sales, Net Sales, Sublicense Income and all of the royalties, fees, and other payments due or paid under this Agreement, as well as the various computations reported under Section 6.1. The records for each
Quarter will be maintained for at least [***] after submission of the applicable report required under Section 6.1. 
 6.4. Audit Rights. Upon
reasonable prior written notice to Company, Company and its Affiliates and Sublicensees will provide Drexel and its accountants with access to all of the books, records and related background information required by Section 6.3 to conduct a
review or audit of Sales, Net Sales, Sublicense Income and all of the royalties, fees, and other payments payable under this Agreement in the preceding [***]. Such accountant and Drexel will enter into a customary confidentiality agreement with
Company. Access will be made available: (a) during normal business hours; (b) in a manner reasonably designed to facilitate Drexel’s review or audit without unreasonable disruption to Company’s business; and (c) no more than
[***] during the Term and for a period of [***] thereafter. Company will [***] pay to Drexel the amount of any underpayment determined by the review or audit, plus accrued interest. If the review or audit determines that Company has underpaid any
payment by [***] or more, then Company will also promptly pay the reasonable out-of-pocket costs and expenses of Drexel and its accountants in connection with the review
or audit. 
 6.5. Information Rights. Until the closing of the Company’s initial public offering, Company will provide to Drexel, on [***]
basis, a summary of Company’s development activities for Licensed Products since the preceding report and, at least as frequently as the following reports are distributed to the Board of Directors or management of Company, copies of all Board
and managerial reports that relate to the Patent Rights, the Technical Information or the Licensed Products. After the closing of the Company’s initial public offering, Company will provide to Drexel, [***] after filing, a copy of each annual
report, proxy statement, 10-K, 10-Q and other material report filed with the U.S. Securities and Exchange Commission. 

6.6. Currency. All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments will be made in United States
dollars. If Company receives payment from a third party in a currency other than United States dollars for which a royalty or fee is owed under this Agreement, then (a) the payment will be converted into United States

  
 6 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 
dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal as of the last business day of the Quarter in which the payment was received
by Company, and (b) the conversion computation will be documented by Company in the applicable report delivered to Drexel under Section 6.1. 

6.7. Place of Payment. All payments by Company are payable to “Drexel University” and will be made to the Payment Address. 

6.8. Interest. All amounts that are not paid by Company when due will accrue interest from the date due until paid at a rate equal to [***] per month
(or the maximum allowed by law, if less). 
  

	7.	 CONFIDENTIALITY 

7.1. Confidentiality Agreement. If Company and Drexel entered into one or more confidential disclosure agreements prior to the Effective Date, then such
agreements will continue to govern the protection of confidential information under this Agreement, and each Affiliate and Sublicensee of Company will be bound to Company’s obligations under such agreements. If, however, no confidential
disclosure agreement has been entered into between Company and Drexel prior to the Effective Date, then in connection with the execution of this Agreement, the parties will enter into a confidential disclosure agreement substantially similar to
Drexel’s standard form. 
 7.2. Other Confidential Matters. Drexel is not obligated to accept any confidential information from Company, except
for the reports required by Sections 4.1, 6.1 and 6.5 and for information disclosed in sublicense agreements in Section 3.4(b) and through the advisory committee in Section 3.6(a). Drexel, acting through its Technology Commercialization
Office, Investigator and personnel working in his laboratory and finance offices, will use reasonable efforts not to disclose to any third party outside of Drexel any confidential information of Company contained in those reports or disclosed
through the advisory committee and will use such information only for purposes of this Agreement, for so long as such information remains confidential. Drexel bears no institutional responsibility for maintaining the confidentiality of any other
information of Company. Company may elect to enter into confidentiality agreements with individual investigators at Drexel that comply with Drexel’s internal policies. 

7.3. Use of Name. Company and its Affiliates, Sublicensees, employees, and agents may not use the name, logo, seal, trademark, or service mark
(including any adaptation of them) of Drexel or any Drexel school, organization, employee, student or representative, without the prior written consent of Drexel, except as required by law or regulation. Drexel and each Drexel school, organization,
employee, student or representative may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Company or its Affiliates, Sublicensees, employees, or agents, without the prior written consent of Company,
except in connection with conflict of interest disclosures in publications, presentations and patent filings or as required by law or regulation. Drexel may not publicly disclose the existence of this Agreement or that it has granted a license to
Company for a period of [***] from the Effective Date without Company’s prior written consent, which may be requested and granted via email. 

  
 7 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 7.4. Publications. Drexel shall be free to publish or present the Improvements and related know-how, after providing Company with a [***] period prior to submission for publication or presentation in which to review each publication or presentation to identify patentable subject matter and to identify any
inadvertent disclosure of Company’s confidential information, which Drexel shall remove from the publication. If necessary to permit the preparation and filing of patent applications, Drexel shall delay submission for publication for an
additional [***]. 
  

	8.	 TERM AND TERMINATION 

8.1. Term. This Agreement will commence on Effective Date and will expire, with respect to any Licensed Product and country, upon the later of
(i) the expiration or abandonment of the last-to-expire Valid Claim of the Patent Rights that covers the sale of such Licensed Product in country, (ii) the
expiration of any granted statutory period of marketing and/or data exclusivity for such Licensed Product that confers an exclusive commercialization period during which Company or any Affiliates or Sublicensees have the exclusive right to market
and sell such Licensed Product in such country through such a regulatory exclusivity right, (iii) the month of the first Sale of a generic equivalent of such Licensed Product in such country and (iv) ten (10) years after the first Sale of
the first Licensed Product. Upon the expiration of this Agreement with respect to any Licensed Product and country, the License with respect to Technical Information for such Licensed Product and country shall become fully-paid, irrevocable and
perpetual. 
 8.2. Early Termination by Company. Company may terminate this Agreement at any time effective upon completion of each of the following
conditions: (a) providing at least sixty (60) days prior written notice to Drexel of such intention to terminate; (b) ceasing to make, have made, use, import, offer for sale and sell all Licensed Products; (c) terminating all
Permitted Sublicenses (subject to any survival thereof as direct licensees pursuant to Section 8.4) and causing all Affiliates and Sublicensees (other than those whose licenses survive) to cease making, having made, using, importing, offering
for sale and selling all Licensed Products; and (d) paying all amounts owed to Drexel under this Agreement and the Sponsored Research Agreement through the effective date of termination. 

8.3. Early Termination by Drexel. Drexel may terminate this Agreement if: (a) Company is more than [***] late in paying to Drexel any amounts owed
under this Agreement and does not pay Drexel in full, including accrued interest, within thirty (30) days after written demand from Drexel; (b) Company or its Affiliate materially breaches this Agreement, including, without limitation,
Company’s failure to meet any Diligence Events, and does not cure the breach within forty-five (45) days after written notice of the breach; provided, however, that with respect to a breach resulting from the Company’s
failure to meet any Diligence Events, if such breach is capable of being cured but not within such forty-five (45) day period, and Company is using commercially reasonable efforts to [***] cure such breach, Company will have an additional
ninety (90) days to cure; (c) Company or its Affiliate experiences a Trigger Event; or (d) Company or its Affiliate challenges, directly or indirectly, whether as a claim, cross claim, counterclaim or defense, the validity or
enforceability of any of the Patent Rights before any court, arbitrator or other tribunal or administrative agency in any jurisdiction. 

  
 8 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 8.4. Effect of Termination. Upon the termination of this Agreement for any reason: (a) the
License terminates; (b) Company and each of its Affiliates and Sublicensees will cease all making, having made, using, importing, offering for sale and selling all Licensed Products, except to extent permitted by Section 8.5, provided that
(i) with respect to any sublicense granted to a Sublicensee that is not in breach of the applicable Sublicense Agreement, Drexel will grant to such Sublicensee, upon written request, license rights under the Patent Rights and the Technical
Information with exclusivity, field, term, financial, and diligence terms equivalent to those in such Sublicense Agreement, and (ii) in no event will Drexel be obligated in such new license agreement: to grant rights to anything Drexel does not
possess or control; to surrender rights Drexel has reserved under Section 3.2; or to take on any new or incremental obligation beyond Drexel’s express obligations under this Agreement; (c) Company will pay to Drexel all amounts,
including accrued interest, owed to Drexel under this Agreement and the Sponsored Research Agreement through the date of termination; (d) Company will, at Drexel’s request, return to the Drexel all confidential information of Drexel and
Company will provide to Drexel one complete copy of all data with respect to Licensed Products generated by Company during the Term that will facilitate the further development of the technology licensed under this Agreement; and (e) in the
case of termination by Drexel, all duties of Drexel and all rights and duties of Company under this Agreement immediately terminate without further action required by either Drexel or Company, except for any surviving rights and obligations under
Section 8.6. 
 8.5. Inventory & Sell Off. Upon the termination of this Agreement for any reason, Company will cause
physical inventories to be taken within [***], which may be extended with Drexel’s written permission of: (a) all completed Licensed Products on hand under the control of Company or its Affiliates or Sublicensees; and (b) such
Licensed Products as are in the process of manufacture and any component parts on the date of termination of this Agreement. Company will deliver [***] to Drexel a copy of the written inventory, certified by an officer of the Company. Upon
termination of this Agreement for any reason, Company will [***] remove, efface or destroy all references to Drexel from any advertising, labels, web sites or other materials used in the promotion of the business of Company or its Affiliates or
Sublicensees, and Company and its Affiliates and Sublicensees will not represent in any manner that it has rights in or to the Patent Rights or the Licensed Products. The above provisions of this Section 8.5 shall not apply to surviving
Sublicenses subject to Section 8.4 above. Upon the termination of this Agreement for any reason other than pursuant to Section 8.3(a) or (c), Company may sell off its inventory of Licensed Products existing on the date of termination for a
period of [***] and pay Drexel royalties on Sales of such inventory within [***] following the expiration of such [***] period. 
 8.6. Survival.
Company’s obligation to pay all amounts, including accrued interest, owed to Drexel under this Agreement will survive the termination of this Agreement for any reason. Sections 15.10 and 15.11 and Articles 6, 7, 8, 11, 12, and 13 will survive
the termination of this Agreement for any reason in accordance with their respective terms. 
  

	9.	 INTELLECTUAL PROPERTY MAINTENANCE AND REIMBURSEMENT 

9.1. Intellectual Property Maintenance. Drexel controls the preparation, prosecution and maintenance of the Patent Rights and the selection of
intellectual property counsel, with input from Company. If, however, Company desires to manage the preparation, prosecution and 

  
 9 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 
maintenance of the Patent Rights with input from Drexel, then Company and Drexel will enter into with intellectual property counsel an Intellectual Property Management Agreement in the form
attached as Exhibit D. Drexel shall not abandon any patent application or patent in the Patent Rights provided Company continues reimbursing Drexel for the prosecution and maintenance thereof. 

9.2. Intellectual Property Reimbursement. 
 (a)
Historic IP Costs. Within [***] after filing of the first IND for the first Licensed Product, the Company will reimburse Drexel for all documented attorneys’ fees, expenses, costs, official fees and all other charges accumulated prior to
the Effective Date incident to the preparation, filing, prosecution and maintenance of the Patent Rights, including any interference negotiations, claims or proceedings. To Drexel’s knowledge, the aggregate amount of intellectual
property costs related to the Patent Rights as of May 31, 2020 is equal to [***]. 
 (b) Ongoing US IP Costs. After the Effective Date, the
Company will either pay directly under a mutually agreeable Intellectual Property Management Agreement or reimburse Drexel for all reasonable and documented attorneys’ fees, expenses, costs, official fees and all other charges incurred on or
after the Effective Date incident to the preparation, filing, prosecution, and maintenance of the Patent Rights in the US, including any interference negotiations, claims or proceedings within [***] after Company’s receipt of invoices for such
fees, costs, expenses and charges. Notwithstanding the foregoing, at any time Company may provide [***] written notice to Drexel that it is no longer interested in supporting any particular patent application or patent. Thereafter, such patent
application or patent will no longer be considered a Patent Right and shall be excluded from the License and Company will have no further payment obligations with respect thereto. For clarity, such exclusion will apply only to the particular patent
application or patent that Company identifies and not any other Patent Right, and in particular will not apply to any Patent Right from which such application or patent claims priority. 

(c) Ongoing Non-US IP Costs. After the Effective Date, Company will either pay directly under a mutually
agreeable Intellectual Property Management Agreement or pay Drexel in advance for all good faith estimates agreed by Company in writing (plus any amounts actually incurred by Drexel in excess of such good faith estimates) for reasonable
attorneys’ fees, expenses, costs, official fees and all other charges incurred after the Effective Date incident to the preparation, filing, prosecution, and maintenance of non-US Patent Rights, within
[***] after Company’s receipt of invoices for such fees, expenses and charges. If Drexel’s good faith estimate of the foregoing fees, costs and expenses (i) is less than the actual reasonable and documented fees, costs and expenses
incurred by Drexel, Company shall [***] pay (i.e., within [***] after receipt of invoice) to Drexel the amount by which Drexel’s actual fees, costs and expenses exceed such good faith estimate from the date of Drexel’s invoice(s)
for such excess amount and (ii) is greater than the actual fees, costs and expenses incurred by Drexel, Drexel shall credit to Company the amount of such excess against any future amounts owed by Company to Drexel. 

  
 10 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

	10.	 INFRINGEMENT 

10.1. Notice. Company and Drexel will notify each other [***] of any actual or threatened infringement of the Patent Rights that may come to their
attention, and will consult each other in a timely manner concerning any appropriate response to the infringement. 
 10.2. Prosecution. Company may
prosecute any infringement of the Patent Rights at Company’s expense. Company must not settle or compromise any such litigation in a manner that imposes any obligations or restrictions on Drexel or grants any rights to the Patent Rights (other
than Permitted Sublicenses) without Drexel’s prior written permission. Financial recoveries from any such litigation will be: (a) first, applied to reimburse Company for its litigation expenditures; and (b) second, as to any
remainder, retained by Company but treated (as appropriate) as either (i) Net Sales for the purpose of determining the royalties due to Drexel under Section 5.6 or (ii) Sublicense Income for the purpose of determining the sublicense
fees due to Drexel under Section 5.6. 
 10.3. Intervention. 

(a) Voluntary Intervention. Drexel reserves the right to voluntarily intervene and join Company in any litigation under Section 10.2, at [***]. If
Drexel voluntarily elects to participate in any such litigation, then in lieu of the division of recoveries specified in Section 10.2, financial recoveries from any such litigation will be shared between Company and Drexel in proportion with
their respective shares of the aggregate Litigation Expenditures by Company and Drexel, then [***] of any amount remaining would be paid to Drexel, and [***] of any amount remaining would be paid to Company, regardless of respective Litigation
Expenditures. 
 (b) Involuntary Participation. If Drexel is required to participate involuntarily in any litigation referred to under
Section 10.2, (such as, for example, but not limited to, being joined or named as a defendant, necessary party, involuntary plaintiff, or indispensable party), then, in lieu of the division of recoveries specified in Section 10.2, (i)
Company will reimburse Drexel’s Litigation Expenditures on an ongoing basis, within [***] of submission of actual invoices; and (ii) financial recoveries from any such litigation will be shared between Company and Drexel as follows:
(1) Company will be reimbursed for all Litigation Expenditures of Company and Litigation Expenditures reimbursed by Company to Drexel; then (2) [***] of any amount remaining would be paid to Drexel, and [***] of any amount remaining will be
paid to Company, regardless of respective Litigation Expenditures. 
 10.4. Drexel Prosecution. If Company does not elect to prosecute the
infringement of the Patent Rights, within [***] of the date on which the parties were notified of such infringement under Section 10.1, then Drexel may elect to prosecute such infringement at Drexel’s expense. If Drexel elects to prosecute
such infringement, then any financial recoveries will be retained by Drexel in their entirety. 
 10.5. Cooperation. In any litigation under this
Article 10, either party, at the request and expense of the other party, will cooperate to the fullest extent reasonably possible; provided, that nothing herein shall permit Company to require Drexel to join in any litigation respecting the
Patent Rights, the Technical Information, the Licensed Products or any other technology licensed under this Agreement, except to the extent that Drexel is required to be joined as described in Section 10.3(b). This Section 10.5 will not be
construed to require either party to undertake any activities, including legal discovery or to join in any litigation, at the request of any third party, except as may be required by lawful process of a court of competent jurisdiction. 

  
 11 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

	11.	 DISCLAIMER OF WARRANTIES 

11.1. Disclaimer. THE PATENT RIGHTS, THE TECHNICAL INFORMATION, THE IMPROVEMENTS, THE LICENSED PRODUCTS AND ANY OTHER TECHNOLOGY LICENSED OR OPTIONED
UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS. DREXEL MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE. 
  

	12.	 LIMITATION OF LIABILITY 

12.1. Limitation of Liability. DREXEL WILL NOT BE LIABLE TO COMPANY, ITS AFFILIATES, SUBLICENSEES, SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY WITH
RESPECT TO ANY CLAIM: (a) ARISING FROM COMPANY’S OR ANY AFFILIATE’S, SUBLICENSEE’S, SUCCESSOR’S, OR ASSIGN’S OR OTHER THIRD PARTY’S USE OF THE PATENT RIGHTS, THE TECHNICAL INFORMATION, THE IMPROVEMENTS, THE
LICENSED PRODUCTS OR ANY OTHER TECHNOLOGY LICENSED OR OPTIONED UNDER THIS AGREEMENT; (b) ARISING FROM THE DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS; OR (c) FOR LOST PROFITS, BUSINESS INTERRUPTION, OR INDIRECT,
SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND. 
  

	13.	 INDEMNIFICATION 

13.1. Indemnification. Company will defend, indemnify, and hold harmless each Indemnified Party from and against any and all Liabilities to the extent
arising from an Indemnification Event, except to the extent arising from the gross negligence or willful misconduct of any Indemnified Party. 
 13.2.
Other Provisions. Company will not settle or compromise any Claim giving rise to Liabilities in any manner that imposes any restrictions or obligations on Drexel or grants any rights to the Patent Rights (other than Permitted Sublicenses) or
the Licensed Products without Drexel’s prior written consent. If Company fails or declines to assume the defense of any Claim within [***] after notice of the Claim, then Drexel may assume the defense of such Claim for the account and at the
risk of Company, and any Liabilities related to such Claim will be conclusively deemed a liability of Company. The indemnification rights of the Indemnified Parties under this Article 13 are in addition to all other rights that an Indemnified Party
may have at law, in equity or otherwise. 
  

	14.	 INSURANCE 

14.1. Coverages. Company will procure and maintain insurance policies for the following coverages with respect to personal injury, bodily injury and
property damage arising out of Company’s performance under this Agreement: (a) during the Term, comprehensive general 

  
 12 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 
liability, including broad form and contractual liability, in a minimum amount of [***] combined single limit per occurrence and in the aggregate; (b) prior to the commencement of clinical
trials involving Licensed Products, clinical trials coverage in a minimum amount of [***] combined single limit per occurrence and in the aggregate; and (c) prior to the Sale of the first Licensed Product, product liability coverage, in a
minimum amount of [***] combined single limit per occurrence and in the aggregate. Drexel may review periodically the adequacy of the minimum amounts of insurance for each coverage required by this Section 14.1 and Drexel reserves the right to
require Company to adjust the limits accordingly. The required 
 minimum amounts of insurance do not constitute a limitation on Company’s liability or
indemnification obligations to Drexel under this Agreement. 
 14.2. Other Requirements. The policies of insurance required by Section 14.1 will
be issued by an insurance carrier with an A.M. Best rating of [***] and will name Drexel as an additional insured with respect to Company’s performance under this Agreement. Company will provide Drexel with insurance certificates evidencing the
required coverage within [***] after the Effective Date and the commencement of each policy period and any renewal periods. Each certificate will provide that the insurance carrier will notify Drexel in writing at least [***] prior to the
cancellation or material change in coverage. 
  

	15.	 ADDITIONAL PROVISIONS 

15.1. Independent Contractors. The parties are independent contractors. Nothing contained in this Agreement is intended to create an agency, partnership
or joint venture between the parties. At no time will either party make commitments or incur any charges or expenses for or on behalf of the other party. 

15.2. No Discrimination. Neither Drexel nor Company will discriminate against any employee or applicant for employment because of race, color, sex,
sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status. 
 15.3. Compliance with Laws. Company must
comply with all prevailing laws, rules and regulations that apply to its activities or obligations under this Agreement. For example, Company will comply with applicable United States export laws and regulations. The transfer of certain technical
data and commodities may require a license from the applicable agency of the United States government and/or written assurances by Company that Company will not export data or commodities to certain foreign countries without prior approval of the
agency. Drexel does not represent that no license is required, or that, if required, the license will issue. 
 15.4. Modification,
Waiver & Remedies. This Agreement may only be modified by a written amendment that is executed by an authorized representative of each party. Any waiver must be express and in writing. No waiver by either party of a breach
by the other party will constitute a waiver of any different or succeeding breach. Unless otherwise specified, all remedies are cumulative. 
 15.5.
Assignment & Hypothecation. Company may not assign this Agreement or any part of it, either directly or by merger or operation of law, without the prior written consent of Drexel, which consent will not be unreasonably
withheld or delayed, provided that: (a) at least [***] 

  
 13 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 
before the proposed transaction, Company gives Drexel written notice and such background information as may be reasonably necessary to enable Drexel to give an informed consent; (b) the
assignee agrees in writing to be legally bound by this Agreement and to deliver to Drexel an updated Development Plan within [***] after the closing of the proposed transaction; and (c) Company provides Drexel with a copy of assignee’s
undertaking. Any permitted assignment will not relieve Company of responsibility for performance of any obligation of Company that has accrued at the time of the assignment. Notwithstanding the foregoing, Company may, without Drexel’s prior
written consent, assign this Agreement, in whole but not in part, (y) to any Affiliate so long as Company remains obligated for all obligations under this Agreement as if such assignment had not occurred and (z) to a third party if all the
following conditions are met: (i) the assignment occurs in connection with a merger, acquisition, consolidation or other business combination or sale or other disposition of all or substantially all of Company’s business or assets relating
to the subject matter hereof and this Agreement is assigned to such acquiror; (ii) Company is in good standing with respect to this Agreement; (iii) assignee has sufficient resources to fulfill all of Company’s diligence and other
obligations under this Agreement; and (iv) prior to the assignment, assignee provides Drexel written confirmation that assignee shall assume all of Company’s interests, rights, duties, liabilities and obligations under this Agreement, and
agrees to comply with all terms and conditions of this Agreement as if assignee were an original party to this Agreement. Company will not grant a security interest in the License or this Agreement during the Term. Any prohibited assignment or
security interest will be null and void. 
 15.6. Notices. Any Notice must be in writing, addressed to the party’s respective Notice Address
listed on the signature page, and delivered: (a) personally; (b) by certified mail, postage prepaid, return receipt requested; or (c) by recognized overnight courier service, charges prepaid. A Notice will be deemed received: if delivered
personally, on the date of delivery; if mailed, five (5) days after deposit in the United States mail; or if sent via courier, one (1) business day after deposit with the courier service. 

15.7. Severability & Reformation. If any provision of this Agreement is held to be invalid or unenforceable by a court of
competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be automatically revised to be a valid or enforceable provision that comes as close as
permitted by law to the parties’ original intent. 
 15.8. Headings & Counterparts. The headings of the articles and
sections included in this Agreement are inserted for convenience only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in several counterparts, all of which taken together will constitute
the same instrument. 
 15.9. Governing Law. This Agreement will be governed in accordance with the laws of the Commonwealth of Pennsylvania, without
giving effect to the conflict of law provisions of any jurisdiction. 
 15.10. Dispute Resolution. If a dispute arises between the parties
concerning any right or duty under this Agreement, then the parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the parties are unable to resolve the dispute amicably, then the parties will submit to the exclusive
jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania with respect to all disputes arising under this Agreement. 

  
 14 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

 15.11. Integration. This Agreement with its Signature Page, Exhibits, the Sponsored Research
Agreement, the Intellectual Property Management Agreement, and the Confidentiality Agreement contain the entire agreement between the parties with respect to the Patent Rights, the Technical Information and the License and supersede all other oral
or written representations, statements, or agreements with respect to such subject matter, including but not limited to the Term Sheet. 

  
 15 

 EXHIBIT A 
  

 Glossary of Terms 

“Affiliate” means a legal entity that is controlling, controlled by or under common control with Company and that has executed either
this Agreement or a written joinder agreement agreeing to be bound by all of the terms and conditions of this Agreement. For purposes of this definition, the word “control” means (i) the direct or indirect ownership of more
than fifty percent (50%) of the outstanding voting securities of a legal entity, (ii) the right to receive fifty percent (50%) or more of the profits or earnings of a legal entity, or (iii) the right to determine the policy decisions of a
legal entity. 
 “Agreement” shall have the meaning set forth on the Signature Page. 

“Claim” means any charges, complaints, actions, suits, proceedings, hearings, investigations, claims or demands. 

“Combination Product” means a product in which one or more active ingredients that are not Licensed Products are sold in combination
with, in addition to, or in a bundle with, a Licensed Product. Such other active ingredient(s) are referred to as the “Other Product(s)”. 

“Confidentiality Agreement” means all confidential disclosure agreements between the parties that remain in effect after the Effective
Date. 
 “Development Plan” means a plan prepared by Company and delivered to Drexel pursuant to Article 4, which shall include, at
a minimum, the information listed on Exhibit C. 
 “Field of Use” means all fields of use covered by the Patent Rights. 

“Generic Equivalent” means, with respect to a Licensed Product, any product that contains the same active pharmaceutical
ingredient as such Licensed Product. 
 “Improvement” means any improvements, analogues, derivatives, modifications,
upgrades, developments or inventions that: (a) are generated, solely by Drexel or jointly by Drexel and Company, after the Effective Date but before the [***] of the Effective Date at Drexel, in the laboratory of Drexel researcher [***], with
respect to which Drexel owns intellectual property rights; (b) are directly related to the Licensed Products or are related to RAD52 or compounds that have been generated to specifically target RAD52; (c) are not subject to the terms and
conditions of any Sponsored Research Agreement between Company and Drexel; and (d) are not otherwise obligated to a third party under the terms of any government grant or sponsored research or other agreement. Improvement does not include any
improvement, analogue, derivative, modification, upgrade, development or invention that is contemplated in the documents attached hereto as Exhibit F as of the Effective Date. 

“Indemnification Event” means any Claim by a third party against one or more Indemnified Parties arising out of or resulting from:
(a) the development, testing, use, manufacture, promotion, sale, distribution or other disposition of any Patent Rights, Technical Information or Licensed Products by Company or its Affiliates or Sublicensees, including, but not limited to,
(i) any product liability or other Claim of any kind related to use by a third party of a Licensed Product, (ii) any Claim by a third party that the use of any Patent Rights or Technical 

  
 EXHIBIT A 

 EXHIBIT A 
  

 
Information or the design, composition, manufacture, use, sale, distribution or other disposition of any Licensed Product by or on behalf of Company or its Affiliates or Sublicensees infringes or
violates any patent, copyright, trade secret, trademark or other intellectual property right of such third party, and (iii) any Claim by a third party relating to any clinical trials or studies for Licensed Products conducted by or on behalf of
Company or its Affiliate or Sublicensees; and (b) any material breach of this Agreement by Company or its Affiliates. 
 “Indemnified
Party” means each of Drexel and its trustees, officers, faculty, agents, contractors, employees and students. 

“Investigator(s)” means the lead investigator(s) of Drexel with respect to the Patent Rights who are specified on the Signature Page.

 “Liabilities” means all damages, awards, settlement amounts, assessments, fines, dues, penalties, costs, fees, liabilities,
obligations, taxes, and expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) that are incurred by an Indemnified Party or awarded or otherwise required to be paid to third
parties by an Indemnified Party. 
 “License” means the license granted by Drexel to Company pursuant to Article 3 of the Terms and
Conditions. 
 “Licensed Products” means products that are made, made for, used, imported, offered for sale or sold by Company or
its Affiliates or Sublicensees and that: (a) in the absence of this Agreement, the manufacture, importation, sale or use thereof would infringe any of the Patent Rights; (b) use or embody, at least in part, the Technical Information; or
(c) use a process covered by a Valid Claim of Patent Rights, in any case, whether or not the claim is issued or pending. 
 “Litigation
Expenditures” means: reasonable attorneys’ fees, court costs, local counsel fees, deposition costs, subpoena costs, court reporter costs, expert fees, and other reasonable expenses directly incurred for investigation or litigation
of Claims. 
 “Net Sales” means the consideration received from each Sale, less [***]. 

Notwithstanding the foregoing, amounts received or invoiced by Company or its Affiliates or Sublicensees for the sale of Licensed Products among Company and
its Affiliates and Sublicensees for further resale [***]. 
 Notwithstanding the foregoing, “Net Sales” [***]. 

Net Sales for a Combination Product shall be calculated as follows: 
  

	(i)	 [***]. 

  

	(ii)	 [***]. 

  

	(iii)	 [***]. 

  

	(iv)	 [***]. 

  
 EXHIBIT A 

 EXHIBIT A 
  

 “Notice” means any notice or other required written communication under this
Agreement. 
 “Notice Address” means the parties’ respective Notice addresses specified on the Signature Page. 

“Patent Rights” means all patent rights represented by or issuing from: (a) the United States patents and patent applications
listed on Exhibit E; (b) any continuation, divisional, reexamination and re-issue applications of (a); and (c) any foreign counterparts and extensions of (a) or (b). 

“Payment Address” means Drexel’s payment address or, in the case of a wire transfer, the electronic transfer information that are
specified on the Signature Page. 
 “Permitted Sublicense” means any sublicense, in whole or in part, of the License under a
Sublicense Agreement. 
 “Qualifying Costs” means the sum of: [***]. 

“Quarter” means each three-month period beginning on January 1, April 1, July 1 and October 1. 

“Sale” means any bona fide transaction for which consideration is received or expected by Company or its Affiliate or Sublicensee for
the sale, use, lease, transfer or other disposition of a Licensed Product to a third party. A Sale is deemed completed [***]. 
 “Sponsored
Research Agreement” means a Sponsored Research Agreement between Drexel and Company entered into simultaneously or in connection with this Agreement. 

“Sublicense Agreement” means an agreement between Company and a Sublicensee, or between Company’s Sublicensee and its further
sublicensee, whereby Company grants a sublicense, in whole or in part, of the License to the Sublicensee, or the Sublicensee grants a sublicense to further sublicensee. 

“Sublicense Income” means the difference equal to: [***]. If Company grants a sublicense to a Sublicensee under the License and also
grants a license under other intellectual property or with respect to products other than Licensed Products, then Company shall [***]. For clarity, Sublicense Income does not include [***]. 

“Sublicensee” means a third-person (excluding an Affiliate of Company) who receives a sublicense, in whole or in part, of the License
directly from Company or an Affiliate or a Sublicensee of Company. 
 “Technical Information” means research and development
information, unpatented inventions, know-how, materials and technical data, whether or not protectable as a trade secret, partially described on Exhibit G and Exhibit F, that: (i) is in the possession of
the Investigator(s) on the Effective Date; and (ii) is needed to produce or use or is related to or was generated in connection with a Licensed Product or Patent Rights. 

  
 EXHIBIT A 

 EXHIBIT A 
  

 “Term” means the term of this Agreement set forth in Section 8.1. 

“Term Sheet” means the non-binding Term Sheet between the parties dated May 1, 2020 with
respect to this Agreement. 
 “Terms and Conditions” means the Terms and Conditions of this Agreement to which this Exhibit A is
attached. 
 “Trigger Event” means any of the following: (a) a material default by Company under the Sponsored Research
Agreement that is not cured during any specified cure periods; (b) if Company or its Affiliate (i) is adjudicated insolvent or bankrupt, (ii) admits in writing its inability to pay its debts, (iii) suffers the appointment of a
custodian, receiver or trustee for it or its property and, if appointed without its consent, not discharged within [***], (iv) makes an assignment for the benefit of creditors, or (v) suffers proceedings being instituted against it under any
law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or release of debtors and, if contested by it, not dismissed or stayed within [***]; (c) the institution or commencement by Company or its Affiliate of any
proceeding under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or release of debtors; (d) the entering of any order for relief relating to any of the proceedings described in (b) or (c) above;
(e) the calling by Company or its Affiliate of a meeting of its creditors with a view to arranging a composition or adjustment of its debts; or (f) the act or failure to act by Company or its Affiliate indicating its consent to, approval
of or acquiescence in any of the proceedings described in (b) – (e) above. 
 “Valid Claim” means: (a) a claim of an
issued and unexpired patent (as may be extended through supplementary protection certificate or patent term extension or the like) that has not been revoked, held invalid, or unenforceable by a patent office or other governmental authority of
competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied, or admitted to be
invalid or unenforceable through reissue, re-examination, or disclaimer or otherwise; or (b) a pending claim of an unissued, pending patent application. 

  
 EXHIBIT A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]